5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/ÜS2016/046497 SALTS OF AN LSD1 INHIBITOR FIELD OF THE INVENTION This application relates to tosylate salts of a lysine specific demethylase-1 (LSD1) inhibitor, including methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of LSD1 mediated diseases such as cancer. BACKGROUND OF THE INVENTION Overexpression of lysine specific demethylase-1 (LSD1) is frequently observed in many types of cancers, including bladder cancer, NSCLC, breast carcinomas, ovary cancer, glioma, colorectal cancer, sarcoma including chondrosarcoma, Ewing’s sarcoma, osteosarcoma, and rhabdomyosarcoma, neuroblastoma, prostate cancer, esophageal squamous cell carcinoma, and papillary thyroid carcinoma. Notably, studies found over¬ expression of LSD1 was significantly associated with clinically aggressive cancers, for example, recurrent prostate cancer, NSCLC, glioma, breast, colon cancer, ovary cancer, esophageal squamous cell carcinoma, and neuroblastoma. In these studies, either knockdown of LSD1expression or treatment with small molecular inhibitors of LSD1 resulted in decreased cancer cell proliferation and/or induction of apoptosis. See, e.g., Hayami, S., et al., Overexprèssion of LSD1 contributes to human carcinogenesis through chromatin regulation in various cancers. Int J Cancer, 2011. 128(3): p. 574-86; Lv, T., et al., Over¬ expression of LSD1 promotes proliferation, migration and invasion in non-small cell lung cancer. PLoS One, 2012. 7(4): p. e35065; Serce, N., et al., Elevated expression ofLSDl (Lysine-specific demethylase 1) during tumour progression from pre-invasive to invasive ductal carcinoma of the breast. BMC Clin Pathol, 2012. 12: p. 13; Lim, S., et al., Lysinespecific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Carcinogenesis, 2010. 31(3): p. 512-20; Konovalov, S. and I. Garcia-Bassets, Analysis of the levels of lysine-specific demethylase 1 (LSD1) mRNA in human ovarian tumors and the effects of chemical LSD1 inhibitors in ovarian cancer cell lines. J Ovarian Res, 2013. 6(1): p. 75; Sareddy, G.R., et al., KDM1 is a novel therapeutic target for the treatment of gliomas. Oncotarget, 2013. 4(1): p. 18-28; Ding, J., et al., LSDl-mediated epigenetic modification contributes to proliferation and metastasis of colon cancer. Br J Cancer, 2013. 109(4): p. 994-1003; Bennani-Baiti, I.M., et al., Lysine- 1 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma. Hum Pathol, 2012. 43(8): p. 1300-7; Schulte, J.H., et al., Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy. Cancer Res, 2009. 69(5): p. 2065-71; Créa, F., et al., The emerging role of histone lysine demethylases in prostate cancer. Mol Cancer, 2012. 11: p. 52; Suikki, H.E., et al., Genetic alterations and changes in expression of histone demethylases in prostate cancer. Prostate, 2010. 70(8): p. 889-98; Yu, Y., et al., High expression of lysine-specific demethylase 1 correlates with poor prognosis of patients with esophageal squamous cell carcinoma. Biochem Biophys Res Commun, 2013. 437(2): p. 192-8; Kong, L., et al., Immunohistochemical expression of RBP2 and LSD1 in papillary thyroid carcinoma. Rom J Morphol Embiyol, 2013. 54(3): p. 499-503. Inhibitors of LSD1 are currently being developed for the treatment of cancer. For example, the molecule l-{[4-(methoxymethyl)-4-({[(lR,2S)-2- phenyIcyclopropy1]amino}methyl)piperidin-1-y1]methyl}cyclobutanecarboxylic acid and other small molecule inhibitors of LSD1 are reported in e.g., US Publication Nos.: 2015- 0225394, 2015-0225375, 2015-0225401, 2015-0225379, 2016-0009720, 2016-0009711, 2016-0009712, and 2016-0009721. Accordingly, there is a need in the art for new forms of LSD1-inhibiting molecules for preparing pharmaceutically useful formulations and dosage forms with suitable properties related to, for example, facilitating the manufacture of safe, effective, and high quality drug products. SUMMARY OF THE INVENTION In one aspect, provided herein are p-toluenesulfonic acid salts of 1-{[4- (methoxymethyl)-4-({[(lR,2S)-2-phenylcyclopropyl]amino}methyl)piperidin-1- yl]methyl}cyclobutanecarboxylic acid, or hydrates or solvates thereof. In some embodiments, provided herein is a crystalline di-tosylate salt of l-{[4-(methoxymethyl)-4- ({[(1R,2S)-2-phenyIcyclopropy1]amino}methyl)piperidin-1-y1]methyl}cyclobutanecarboxylic acid. In another aspect, provided herein is a pharmaceutical composition, which includes the p-toluenesulfonic acid salt of l-{[4-(methoxymethyl)-4-({[(lR,2S)-2- phenyIcyclopropy1]amino}methyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid. 2 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 In another aspect, provided herein is a method of inhibiting LSD1 using the salts and crystalline forms as described herein. In another aspect, provided herein are therapeutic methods of using the salts and crystalline forms as described herein. In another aspect, provided herein are processes for preparing the salts and crystalline forms as described herein. In another aspect, provided herein are intermediates useful for the preparation of the salts and crystalline forms described herein. BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 shows an X-ray powder diffraction (XRPD) pattern of Compound I di-tosylate salt, Form I. FIG. 2 shows a DSC thermogram of Compound I di-tosylate salt, Form I. FIG. 3 shows a TGA thermogram of Compound I di-tosylate salt, Form I. FIG. 4 shows an XRPD pattern of Compound I di-tosylate salt, Form HI. FIG. 5 shows a DSC thermogram of Compound I di-tosylate salt, Form HI. FIG. 6 shows a TGA thermogram of Compound I di-tosylate salt, Form HI. FIG. 7 shows an XRPD pattern of Compound I di-tosylate salt, Form HII. FIG. 8 shows a DSC thermogram of Compound I di-tosylate salt, Form HII. FIG. 9 shows a TGA thermogram of Compound I di-tosylate salt, Form HII. FIG. 10 shows an XRPD pattern of Compound I di-tosylate salt, Form Hill. FIG. 11 shows a DSC thermogram of Compound I di-tosylate salt, Form Hill. FIG. 12 shows a TGA thermogram of Compound I di-tosylate salt, Form Hill. FIG. 13 shows an XRPD pattern of Compound I di-tosylate salt, Form DH. FIG. 14 shows a DSC thermogram of Compound I di-tosylate salt, Form DH. FIG. 15 shows a TGA thermogram of Compound I di-tosylate salt, Form DH. FIG. 16 shows a DVS adsorption-desorption isotherm of Compound I di-tosylate salt, Form I. FIG. 17 shows a DVS adsorption-desorption isotherm of Compound I di-tosylate salt, Form HI. FIG. 18 shows a DVS adsorption-desorption isotherm of Compound I di-tosylate salt, Form DH. 3 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 FIG. 19 shows an XRPD pattern of Compound I di-tosylate salt. Form II. FIG. 20 shows a DSC thermogram of Compound I di-tosylate salt, Form II. FIG. 21 shows a TGA thermogram of Compound I di-tosylate salt, Form II. FIG. 22 shows an XRPD pattern of Compound I di-tosylate salt, Form III. FIG. 23 shows a DSC thermogram of Compound I di-tosylate salt, Form III. FIG. 24 shows a TGA thermogram of Compound I di-tosylate salt, Form III. FIG. 25 shows an XRPD pattern of Compound I di-tosylate salt, Form Illa. FIG. 26 shows an XRPD pattern of Compound I di-tosylate salt, Form IV. FIG. 27 shows a DSC thermogram of Compound I di-tosylate salt, Form IV. FIG. 28 shows a TGA thermogram of Compound I di-tosylate salt, Form IV. FIG. 29 shows an XRPD pattern of Compound I di-tosylate salt, Form IVa. FIG. 30 shows a DSC thermogram of Compound I di-tosylate salt, Form IVa. FIG. 31 shows a TGA thermogram of Compound I di-tosylate salt, Form IVa. FIG. 32 shows an XRPD pattern of Compound I di-tosylate salt, Form V. FIG. 33 shows a DSC thermogram of Compound I di-tosylate salt, Form V. FIG. 34 shows a TGA thermogram of Compound I di-tosylate salt, Form V. FIG. 35 shows an XRPD pattern of Compound I di-tosylate salt, Form VI. FIG. 36 shows a DSC thermogram of Compound I di-tosylate salt, Form VI. FIG. 37 shows a TGA thermogram of Compound I di-tosylate salt, Form VI. FIG. 38 shows an XRPD pattern of Compound I di-tosylate salt, Form VII. FIG. 39 shows a DSC thermogram of Compound I di-tosylate salt, Form VII. FIG. 40 shows a TGA thermogram of Compound I di-tosylate salt, Form VII. FIG. 41 shows an XRPD pattern of Compound I di-tosylate salt, Form VIII. FIG. 42 shows a DSC thermogram of Compound I di-tosylate salt, Form VIII. FIG. 43 shows a TGA thermogram of Compound I di-tosylate salt, Form VIII. FIG. 44 shows an XRPD pattern of Compound I di-tosylate salt, Form IX. FIG. 45 shows a DSC thermogram of Compound I di-tosylate salt, Form IX. FIG. 46 shows a TGA thermogram of Compound I di-tosylate salt, Form IX. FIG. 47 shows an XRPD pattern of Compound I di-tosylate salt, FormX. FIG. 48 shows a DSC thermogram of Compound I di-tosylate salt, FormX. FIG. 49 shows a TGA thermogram of Compound I di-tosylate salt, Form X. FIG. 50 shows an XRPD pattern of Compound I di-tosylate salt, Form XI. 4 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 FIG. 51 shows a DSC thermogram of Compound I di-tosylate salt. Form XI. FIG. 52 shows a TGA thermogram of Compound I di-tosylate salt, Form XI. FIG. 53 shows an XRPD pattern of Compound I di-tosylate salt, Form XII. FIG. 54 shows a DSC thermogram of Compound I di-tosylate salt, Form XII. FIG. 55 shows a TGA thermogram of Compound I di-tosylate salt, Form XII. FIG. 56 shows an XRPD pattern of amorphous Compound I di-tosylate salt. DETAILED DESCRIPTION General The present disclosure relates to acid salts of an LSD1 inhibitor and crystalline forms thereof. Specifically, provided herein are p-toluenesulfonic acid (tosylic acid) salts of an LSD1 inhibitor and crystalline forms thereof. The salts and crystalline forms described herein have many advantages, for example they have desirable properties, such as ease of handling, ease of processing, storage stability, and ease of purification. Moreover, the salts and crystalline forms can be useful for improving the performance characteristics of a pharmaceutical product such as dissolution profile, shelf-life and bioavailability. Definition As used herein, the term "Ci-jalkyl," employed alone or in combination with other terms, refers to a saturated hydrocarbon group that may be straight-chain or branched, having i to j carbons. In some embodiments, the alkyl group contains from 1 to 6 carbon atoms or from 1 to 4 carbon atoms, or from 1 to 3 carbon atoms. Examples of alkyl moieties include, but are not limited to, chemical groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sbutyl, and t-butyl. As used herein, the term "Ci-j alkoxy," employed alone or in combination with other terms, refers to a group of formula -O-alkyl, wherein the alkyl group has i to j carbons. Example alkoxy groups include methoxy, ethoxy, and propoxy (e g., n-propoxy and isopropoxy). In some embodiments, the alkyl group has 1 to 3 carbon atoms. As used herein, the term "halo" or “halogen” employed alone or in combination with other terms, refers to a halogen atom selected from F, Cl, I or Br. In some embodiments, "halo" or “halogen” refers to a halogen atom selected from F, Cl, or Br. In some 5 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 embodiments, the halo substituent is Cl or Br. In some embodiments, the halo substituent is Cl. As used herein, the term "Ci-jhaloalkyl," employed alone or in combination with other terms, refers to an alkyl group having from one halogen atom to 2s+l halogen atoms which may be the same or different, where "s" is the number of carbon atoms in the alkyl group, wherein the alkyl group has i to j carbon atoms. In some embodiments, the haloalkyl group is fluorinated only. In some embodiments, the haloalkyl group is fluoromethyl, difluoromethyl, or trifluoromethyl. In some embodiments, the haloalkyl group is trifluoromethyl. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms. As used herein, "Ci-jhaloalkoxy," employed alone or in combination with other terms, refers to a group of formula -O-haloalkyl having i to j carbon atoms. An example haloalkoxy group is OCF3. An additional example haloalkoxy group is OCHF2. In some embodiments, the haloalkoxy group is fluorinated only. In some embodiments, the alkyl group has 1 to 6 or 1 to 4 carbon atoms. In some embodiments, the haloalkoxy group is Cm haloalkoxy. As used herein, "protecting group" refers to a grouping of atoms that when attached to a reactive group in a molecule masks, reduces or prevents that reactivity. Examples of protecting groups can be found in T.W. Greene and P.G. Wuts, Protective Groups in Organic Synthesis, (Wiley, 4th ed. 2006), Beaucage and Iyer, Tetrahedron 48:2223-23 1 1 (1992), and Harrison and Harrison et al, Compendium of Synthetic Organic Methods, Vols. 1 -8 (John Wiley and Sons. 1971 - 1996). Representative amino protecting groups include formyl, acetyl, trifluoroacetyl, benzyl, benzyloxycarbonyl (CBZ), tert-butoxycarbonyl (Boc), trimethyl silyl (TMS), 2-trimethylsilyl-ethanesulfonyl (SES), trityl and substituted trityl groups, allyloxycarbonyl, 9-fluorenylmethyloxycarbonyl (FMOC), nitro-veratryloxycarbonyl (NVOC), tri-isopropylsilyl (TIPS), phenylsulphonyl and the like (see also, Boyle, A. L. (Editor), carbamates, amides, N-sulfonyl derivatives, groups of formula -C(O)OR, wherein R is, for example, methyl, ethyl, t-butyl, benzyl, phenylethyl, CH2=CHCH2-, and the like, groups of the formula -C(O)R', wherein R' is, for example, methyl, phenyl, trifluoromethyl, and the like, groups of the formula -SO2R", wherein R" is, for example, tolyl, phenyl, trifluoromethyl, 2,2,5,7,8-pentamethylchroman-6-yl, 2,3,6-trimethyl-4-methoxyphenyl, and the like, and silanyl containing groups, such as 2-trimethylsilylethoxymethyl, tbutyldimethylsilyl, triisopropylsilyl, and the like. Carboxyl protecting group include moieties that are capable of forming esters with the carboxyl. For example, carboxyl protecting 6 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 groups and carboxyl can form substituted methyl esters, 2-substituted ethyl esters, 2,6- dialkylphenylesters, silyl esters, substituted benzylesters, and the like. Representative carboxyl protecting groups include benzyl, 9-fluorenylmethyl, methoxymethyl, t-butyl, 2,2,2- trichloroethyl, 2-(trimethylsilyl)ethyl, tetrahydropyranyl, benzoxymethyl, pentafluorophenyl, triphenylmethyl, diphenylmethyl, nitrobenzyl, trimethylsilyl, triethylsilyl, tbutyldimethylsilyl, and the like. As used herein, TsOH refers to p-toluenesulfonic acid, 4-methylbenzenesulfonic acid, or tosylic acid. As used herein, and unless otherwise specified, the term "about", when used in connection with a numeric value or range of values which is provided to describe a particular salt or solid form, e g., a specific temperature or temperature range, such as, for example, that describing a melting, dehydration, or glass transition; a mass change, such as, for example, a mass change as a function of temperature or humidity; a solvent or water content, in terms of, for example, mass or a percentage; or a peak position, such as, for example, in analysis by, for example, 13C NMR, DSC, TGA and XRPD; indicate that the value or range of values may deviate to an extent deemed reasonable to one of ordinary skill in the art while still describing the particular solid form. Specifically, the term "about", when used in this context, indicates that the numeric value or range of values may vary by 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2% or 0.1% of the recited value or range of values while still describing the particular solid form. The term "about", when used in reference to a degree 2-theta value refers to +/-0.3 degrees 2-theta or +/-0.2 degrees 2-theta. As used herein, the term “peak” or “characteristic peak” refers to a reflection having a relative height/intensity of at least about 3% of the maximum peak height/intensity. As used herein, the term "ciystalline" or "crystalline form" refers to a crystalline solid form of a chemical compound, including, but not limited to, a single-component or multiple¬ component crystal form, e.g.. including solvates, hydrates, clathrates, and a co-crystals. The term “crystalline form” is meant to refer to a certain lattice configuration of a crystalline substance. Different crystalline forms of the same substance typically have different crystalline lattices (e.g., unit cells), typically have different physical properties attributed to their different crystalline lattices, and in some instances, have different water or solvent content. The different crystalline lattices can be identified by solid state characterization methods such as by X-ray powder diffraction (XRPD). Other characterization methods such 7 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 as differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), dynamic vapor sorption (DVS), and the like further help identify the crystalline form as well as help determine stability and solvent/water content. Different crystalline forms of a particular substance, such as a salt of the invention, can include both anhydrous forms of that substance and solvated/hydrated forms of that substance, where each of the anhydrous forms and solvated/hydrated forms are distinguished from each other by different XRPD patterns, or other solid state characterization methods, thereby signifying different crystalline lattices. In some instances, a single crystalline form (e.g., identified by a unique XRPD pattern) can have variable water or solvent content, where the lattice remains substantially unchanged (as does the XRPD pattern) despite the compositional variation with respect to water and/or solvent. An XRPD pattern of reflections (peaks) is typically considered a fingerprint of a particular crystalline form. It is well known that the relative intensities of the XRPD peaks can widely vary depending on, inter alia, the sample preparation technique, crystal size distribution, filters used, the sample mounting procedure, and the particular instrument employed. In some instances, new peaks may be observed or existing peaks may disappear, depending on the type of the machine or the settings (for example, whether a Ni filter is used or not). As used herein, the term “peak” refers to a reflection having a relative height/intensity of at least about 3% or at least about 4% of the maximum peak height/intensity. Moreover, instrument variation and other factors can affect the 2-theta values. Thus, peak assignments, such as those reported herein, can vary by plus or minus about 0.2° (2-theta) or about 0.3° (2-theta), and the term “substantially” as used in the context of XRPD herein is meant to encompass the above-mentioned variations. In the same way, temperature readings in connection with DSC, TGA, or other thermal experiments can vary about ±3 °C depending on the instrument, particular settings, sample preparation, etc. Accordingly, a crystalline form reported herein having a DSC thermogram “substantially” as shown in any of the Figures is understood to accommodate such variation. Crystalline forms of a substance can be obtained by a number of methods, as known in the art. Such methods include, but are not limited to, melt recrystallization, melt cooling, solvent recrystallization, recrystallization in confined spaces such as, e.g., in nanopores or capillaries, recrystallization on surfaces or templates such as, e.g., on polymers, 8 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 reciystallization in the presence of additives, such as, e.g., co-crystal counter-molecules, desolvation, dehydration, rapid evaporation, rapid cooling, slow cooling, vapor diffusion, sublimation, exposure to moisture, grinding and solvent-drop grinding. As used herein, the term "amorphous" or "amorphous form" is intended to mean that the substance, component, or product in question is not substantially crystalline as determined, for instance, by XRPD or where the substance, component, or product in question, for example is not biréfringent when viewed microscopically. In certain embodiments, a sample comprising an amorphous form of a substance may be substantially free of other amorphous forms and/or crystalline forms. For example, an amorphous substance can be identified by an XRPD spectrum having an absence of reflections. In some embodiments, the salts (or hydrates and solvates thereof) of the invention are prepared in batches referred to as batches, samples, or preparations. The batches, samples, or preparations can include the salts of the invention in any of the crystalline or non-crystalline forms described herein, included hydrated and non-hydrated forms, and mixtures thereof. The term “hydrate,” as used herein, is meant to refer to a solid form of Compound I di-tosylate salt that includes water. The water in a hydrate can be present in a stoichiometric amount with respect to the amount of salt in the solid, or can be present in varying amounts, such as can be found in connection with channel hydrates. As used herein, the term "crystalline purity," means percentage of a crystalline form in a preparation or sample which may contain other forms such as an amorphous form of the same compound, or at least one other crystalline form of the compound, or mixtures thereof. As used herein, the term "substantially crystalline," means a majority of the weight of a sample or preparation of a salt (or hydrate or solvate thereof) of the invention is crystalline and the remainder of the sample is a non-crystalline form (e.g., amorphous form) of the same compound. In some embodiments, a substantially crystalline sample has at least about 95% crystallinity (e.g., about 5% of the non-crystalline form of the same compound), preferably at least about 96% ciystallinity (e.g., about 4% of the non-crystalline form of the same compound), more preferably at least about 97% crystallinity (e.g., about 3% of the non¬ crystalline form of the same compound), even more preferably at least about 98% crystallinity (e.g., about 2% of the non-crystalline form of the same compound), still more preferably at least about 99% crystallinity (e.g., about 1% of the non-crystalline form of the same compound), and most preferably about 100% crystallinity (e.g., about 0% of the non- 9 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 crystalline form of the same compound). In some embodiments, the term “fully crystalline” means at least about 99% or about 100% crystallinity. The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, immunogenicity or other problem or complication, commensurate with a reasonable benefit/risk ratio. As used herein, the phrase "pharmaceutically acceptable carrier or excipient" refers to a pharmaceutically-acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, solvent, or encapsulating material. Excipients or carriers are generally safe, non-toxic and neither biologically nor otherwise undesirable and include excipients or carriers that are acceptable for veterinary use as well as human pharmaceutical use. In one embodiment, each component is "pharmaceutically acceptable" as defined herein. See, e.g., Remington: The Science and Practice of Pharmacy, 21st ed.; Lippincott Williams & Wilkins: Philadelphia, Pa., 2005; Handbook of Pharmaceutical Excipients, 6th ed.; Rowe et al., Eds.; The Pharmaceutical Press and the American Pharmaceutical Association: 2009; Handbook of Pharmaceutical Additives, 3rd ed.; Ash and Ash Eds.; Gower Publishing Company: 2007; Pharmaceutical Preformulation and Formulation, 2nd ed.; Gibson Ed.; CRC Press LLC: Boca Raton, Fla., 2009. As used herein, the term "contacting" refers to the bringing together of indicated moieties in an in vitro system or an in vivo system. For example, "contacting" a LSD1 enzyme with a compound of the invention includes the administration of a compound of the present invention to an individual or patient, such as a human, having a LSD1 enzyme, as well as, for example, introducing a compound of the invention into a sample containing a cellular or purified preparation containing the LSD1 enzyme. As used herein, the term "individual" or "patient, " used interchangeably, refers to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, swine, cattle, sheep, horses, or primates, and most preferably humans. As used herein, the phrase "therapeutically effective amount" refers to the amount of active compound or pharmaceutical agent that elicits the biological or medicinal response that is being sought in a tissue, system, animal, individual or human by a researcher, veterinarian, medical doctor or other clinician. The therapeutically effective amount will vary depending 10 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 on the compound, the disease, disorder or condition and its severity and the age, weight, etc., of the mammal to be treated. In general, satisfactory results in subjects are indicated to be obtained at a daily dosage of from about 0.1 to about 10 g/kg subject body weight. In some embodiments, a daily dose ranges from about 0.10 to 10.0 mg/kg of body weight, from about 1.0 to 3.0 mg/kg of body weight, from about 3 to 10 mg/kg of body weight, from about 3 to 150 mg/kg of body weight, from about 3 to 100 mg/kg of body weight, from about 10 to 100 mg/kg of body weight, from about 10 to 150 mg/kg of body weight, or from about 150 to 1000 mg/kg of body weight. The dosage can be conveniently administered, e.g., in divided doses up to four times a day or in sustained-release form. As used herein, the term "treating" or "treatment" refers to inhibiting the disease; for example, inhibiting a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (z.e.„ arresting further development of the pathology and/or symptomatology) or ameliorating the disease; for example, ameliorating a disease, condition or disorder in an individual who is experiencing or displaying the pathology or symptomatology of the disease, condition or disorder (z.e.„ reversing the pathology and/or symptomatology) such as decreasing the severity of disease. As used herein, the term “reacting” is used as known in the art and generally refers to the bringing together of chemical reagents in such a manner so as to allow their interaction at the molecular level to achieve a chemical or physical transformation. In some embodiments, the reacting involves at least two reagents, wherein one or more equivalents of second reagent are used with respect to the first reagent. In some embodiments, the reacting step of a synthetic process may involve one or more substances in addition to the reagents such as solvent and/or a catalyst. The reacting steps of the processes described herein can be conducted for a time and under conditions suitable for preparing the identified product. As used herein, the terms “combining” and “mixing” with respect to reagents of a chemical reaction are used interchangeably with the term “reacting” herein. The term “coupling” also can be considered interchangeable with “reacting” but may be used in conjunction with a reaction step that involves the linking of two organic fragments. p-Toluenesulfonic acid salt 11 5 10 15 20 25 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 In one aspect, the present disclosure provides p-toluene sulfonic acid (or tosylic acid) salts of 1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenyIcyclopropy1]amino}methyl)piperidinI -yl]methyl}cyclobutanecarboxylic acid, or hydrates or solvates thereof. Compound I refers to 1-{[4-(methoxymethyl)-4-({[(1R,2S)-2-phenylcyclopropy1]amino}methyl)piperidin-1- yl]methyl}cyclobutanecarboxylic acid having the formula: Compound I In some embodiments, the present disclosure provides l-{[4-(methoxymethyl)-4-({[(lR,2S)- 2-phenylcyclopropyl]amino}methyl)piperidin-l-yl]methyl}cyclobutanecarboxylic acid bis(4- methylbenzenesulfonate), which is shown below and referred to herein as “Compound I di¬ tosylate salt,” “Compound I bis-p-toluenesulfonic acid,” “Compound I bis-p-toluenesulfonic acid salt,” “Compound I di-p-toluenesulfonic acid,” “Compound I di-p-toluenesulfonic acid salt,” “Compound I bis(4-methylbenzenesulfonate),” or l-{[4-(methoxymethyl)-4- ({[(1R,2S)-2-phenyIcyclopropy1]amino}methyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid di-tosylate salt. •2TsOH Compound I di-tosylate salt It will be understood that atosylate salt of !-{[4-(methoxymethyl)-4-({[(lR,2S)-2- phenyIcyclopropy1]amino}methyl)piperidin-1-y1]methyl}cyclobutanecarboxylic acid comprises a cation of l-{[4-(methoxymethyl)-4-({[(lR,2S)-2- phenylcyclopropyl]amino}methyl)piperidin-l-yl]methyl}cyclobutanecarboxylic acid (e g., in one embodiment, protonated at one atomic position, or in other embodiments, protonated at more than one atomic position) and at least one anion of p-toluenesulfonic acid, where the anion is referred to herein as "tosylate" according to convention. In certain embodiments, solid forms of l-{[4-(methoxymethyl)-4-({[(lR,2S)-2- phenyIcyclopropy1]amino}methyl)piperidin-1-y1]methyl}cyclobutanecarboxylic acid tosylate salt will comprise l-{[4-(methoxymethyl)-4-({[(lR,2S)-2- phenylcyclopropyl]amino}methyl)piperidin-l-yl]methyl}cyclobutanecarboxylic acid and p- 12 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 toluenesulfonic acid with a molar ratio of about 1:1. In certain embodiments, solid forms of l-{[4-(methoxymethyl)-4-({[(lR,2S)-2-phenylcyclopropyl]amino}methyl)piperidin-lyl]methyl}cyclobutanecarboxylic acid di-tosylate salt comprise l-{[4-(methoxymethyl)-4- ({[(1R,2S)-2-phenyIcyclopropy1]amino}methyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid and p-toluenesulfonic acid with a molar ratio of 1:2. In one embodiment, the molar ratio of Compound I to p-toluenesulfonic acid in the salt is about 1:2. In another embodiment, the molar ratio of Compound I to p-toluenesulfonic acid in the salt is about 1:1. In another embodiment, the molar ratio of Compound I to ptoluenesulfonic acid in the salt is about 1:1.5. In another embodiment, the molar ratio of Compound I to p-toluenesulfonic acid in the salt is about 1:0.5. In another embodiment, the molar ratio of Compound I to p-toluenesulfonic acid in the salt is about 1:2.5. In another embodiment, the molar ratio of Compound I to p-toluenesulfonic acid in the salt is between about 1:0.5 and about 1:2. In some embodiments, the p-toluenesulfonic acid salt of Compound I is a hydrate. In some embodiments, the p-toluenesulfonic acid salt of Compound I is an anhydrate. In some embodiments, the p-toluenesulfonic acid salt of Compound I is mono-hydrate (e.g., the molar ratio of the salt to water is about 1:1). In some embodiments, the p-toluenesulfonic acid salt of Compound I is a di-hydrate (e.g., the molar ratio of the salt to water is about 1:2). In some embodiments, the p-toluenesulfonic acid salt of Compound I is a hemi-hydrate (e.g., the molar ratio of the salt to water is about 2:1). In some embodiments, the p-toluenesulfonic acid salt of Compound I has one or more molecules of water per molecule of salt. The tosylate salts of Compound I are LSD1 inhibitors useful in the treatment of diseases. The advantages of the tosylic acid salt of Compound I include high crystallinity, high melting point, stable crystalline form, and non-hygroscopic properties, each of which facilitates the purification, reproducibility, scale up, manufacturing, and formulation of the drug compound. Compound I p-toluenesulfonic acid salt can be prepared as an amorphous solid, as a crystalline solid, or as a mixture thereof. In some embodiments, Compound I ptoluenesulfonic acid salt is a di-tosylate salt. In some embodiments, Compound I di-tosylate salt is substantially crystalline. In certain embodiments, Compound I di-tosylate salt has a crystalline purity of at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%. 13 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 In some embodiments. Compound I di-tosylate salt is ciystalline with a crystalline purity of about 100%. Form I of Compound I di-tosylate salt In some embodiments, the crystalline solid has Form I, which is described below in the Examples. In some embodiments. Form I has at least one characteristic XRPD peak, in terms of 2-theta, at about 3.6 (e g.. 3.6 ± 0.3 or 3.6 ± 0.2) degrees. In some embodiments, Form I has at least one characteristic XRPD peak, in terms of 2-theta, at about 4.9 (e.g., 4.9 ± 0.3 or 4.9 ± 0.2) degrees. In some embodiments, Form I has at least one characteristic XRPD peak, in terms of 2-theta, at about 6.2 (e.g., 6.2 ± 0.3 or 6.2 ± 0.2) degrees. In some embodiments, Form I has at least one characteristic XRPD peak, in terms of 2-theta, at about 7.7 (e.g., 7.7 ± 0.3 or 7.7 ± 0.2) degrees. In some embodiments, Form I has at least one characteristic XRPD peak, in terms of 2-theta, at about 22.7 (e.g., 22.7 ± 0.3 or 22.7 ± 0.2) degrees. In some embodiments, Form I has at least one characteristic XRPD peak, in terms of 2-theta, at about 4.9 (e.g., 4.9 ± 0.3 or 4.9 ± 0.2) or about 6.2 (e.g., 6.2 ± 0.3 or 6.2 ± 0.2) degrees. In some embodiments, Form I has at least one characteristic XRPD peak, in terms of 2-theta, at about 3.6 (e.g., 3.6 ± 0.3 or 3.6 ± 0.2), about 4.9 (e.g., 4.9 ± 0.3 or 4.9 ± 0.2), or about 6.2 (e.g., 6.2 ± 0.3 or 6.2 ± 0.2) degrees. In some embodiments, Form I has two or more characteristic XRPD peaks, in terms of 2-theta, selected from about 3.6 (e.g., 3.6 ± 0.3 or 3.6 ± 0.2), about 4.9 (e.g., 4.9 ± 0.3 or 4.9 ± 0.2), about 6.2 (e.g., 6.2 ± 0.3 or 6.2 ± 0.2), about 7.7 (e.g., 7.7 ± 0.3 or 7.7 ± 0.2) and about 22.7 (e.g., 22.7 ± 0.3 or 22.7 ± 0.2) degrees. In some embodiments, Form I has two or more characteristic XRPD peaks, in terms of 2- theta, selected from at about 3.6 (e.g., 3.6 ± 0.3 or 3.6 ± 0.2), about 4.9 (e.g., 4.9 ± 0.3 or 4.9 ± 0.2), about 6.2 (6.2 ± 0.3 or 6.2 ± 0.2), about 7.7 (e.g., 7.7 ± 0.3 or 7.7 ± 0.2), about 22.7 (e.g., 22.7 ± 0.3 or 22.7 ± 0.2), about 8.9 (e.g., 8.9 ± 0.3 or 8.9 ± 0.2), about 10.0 (e.g., 10.0 ± 0.3 or 10.0 ± 0.2), about 11.5 (e.g., 11.5 ± 0.3 or 11.5 ± 0.2), about 14.3 (e.g., 14.3 ± 0.3 or 14.3 ± 0.2), about 15.0 (e.g., 15.0 ± 0.3 or 15.0 ± 0.2), about 15.5 (e.g., 15.5 ± 0.3 or 15.5 ± 0.2), about 16.3 (e.g., 16.3 ± 0.3 or 16.3 ± 0.2), about 17.8 (e.g., 17.8 ± 0.3 or 17.8 ± 0.2), about 19.1 (e.g., 19.1 ± 0.3 or 19.1 ± 0.2), about 19.8 (e.g., 19.8 ± 0.3 or 19.8 ± 0.2), about 20.9 (e.g., 20.9 ± 0.3 or 20.9 ± 0.2), and about 22.2 (e.g, 22.2 ± 0.3 or 22.2 ± 0.2) degrees. In some embodiments, Form I has three or more characteristic XRPD peaks, in terms of 2- theta, selected from about 3.6 (e.g., 3.6 ± 0.3 or 3.6 ± 0.2), about 4.9 (e.g., 4.9 ± 0.3 or 4.9 ± 14 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 0.2), about 6.2 (6.2 ± 0.3 or 6.2 ± 0.2), about 7.7 (e.g., 7.7 ± 0.3 or 7.7 ± 0.2), about 22.7 (e.g., 22.7 ± 0.3 or 22.7 ± 0.2), about 8.9 (e.g., 8.9 ± 0.3 or 8.9 ± 0.2), about 10.0 (e.g., 10.0 ± 0.3 or 10.0 ± 0.2), about 11.5 (e.g., 11.5 ± 0.3 or 11.5 ± 0.2), about 14.3 (e.g., 14.3 ± 0.3 or 14.3 ± 0.2), about 15.0 (e.g., 15.0 ± 0.3 or 15.0 ± 0.2), about 15.5 (e.g., 15.5 ± 0.3 or 15.5 ± 0.2), about 16.3 (e.g., 16.3 ± 0.3 or 16.3 ± 0.2), about 17.8 (e.g., 17.8 ± 0.3 or 17.8 ± 0.2), about 19.1 (e.g., 19.1 ± 0.3 or 19.1 ± 0.2), about 19.8 (e.g., 19.8 ± 0.3 or 19.8 ± 0.2), about 20.9 (e.g., 20.9 ± 0.3 or 20.9 ± 0.2), and about 22.2 (e.g., 22.2 ± 0.3 or 22.2 ± 0.2) degrees. In some embodiments, Form I has four or more characteristic XRPD peaks, in terms of 2- theta, selected from about 3.6 (e.g., 3.6 ± 0.3 or 3.6 ± 0.2), about 4.9 (e.g., 4.9 ± 0.3 or 4.9 ± 0.2), about 6.2 (6.2 ± 0.3 or 6.2 ± 0.2), about 7.7 (e.g., 7.7 ± 0.3 or 7.7 ± 0.2), about 22.7 (e.g., 22.7 ± 0.3 or 22.7 ± 0.2), about 8.9 (e.g., 8.9 ± 0.3 or 8.9 ± 0.2), about 10.0 (e.g., 10.0 ± 0.3 or 10.0 ± 0.2), about 11.5 (e.g., 11.5 ± 0.3 or 11.5 ± 0.2), about 14.3 (e.g., 14.3 ± 0.3 or 14.3 ± 0.2), about 15.0 (e.g., 15.0 ± 0.3 or 15.0 ± 0.2), about 15.5 (e.g., 15.5 ± 0.3 or 15.5 ± 0.2), about 16.3 (e.g., 16.3 ± 0.3 or 16.3 ± 0.2), about 17.8 (e.g., 17.8 ± 0.3 or 17.8 ± 0.2), about 19.1 (e.g., 19.1 ± 0.3 or 19.1 ± 0.2), about 19.8 (e.g., 19.8 ± 0.3 or 19.8 ± 0.2), about 20.9 (e.g., 20.9 ± 0.3 or 20.9 ± 0.2), and about 22.2 (e.g., 22.2 ± 0.3 or 22.2 ± 0.2) degrees. In some embodiments, Form I has an X-ray powder diffraction pattern comprising one or more characteristic peaks selected from about 3.6 (e.g., 3.6 ± 0.3 or 3.6 ± 0.2), about 4.9 (e.g., 4.9 ± 0.3 or 4.9 ± 0.2), about 6.2 (6.2 ± 0.3 or 6.2 ± 0.2), about 7.7 (e.g., 7.7 ± 0.3 or 7.7 ± 0.2), about 22.7 (e.g., 22.7 ± 0.3 or 22.7 ± 0.2), about 8.9 (e.g., 8.9 ± 0.3 or 8.9 ± 0.2), about 10.0 (e.g., 10.0 ± 0.3 or 10.0 ± 0.2), about 11.5 (e.g., 11.5 ± 0.3 or 11.5 ± 0.2), about 14.3 (e.g., 14.3 ± 0.3 or 14.3 ± 0.2), about 15.0 (e.g., 15.0 ± 0.3 or 15.0 ± 0.2), about 15.5 (e.g., 15.5 ± 0.3 or 15.5 ± 0.2), about 16.3 (e.g., 16.3 ± 0.3 or 16.3 ± 0.2), about 17.8 (e.g., 17.8 ± 0.3 or 17.8 ± 0.2), about 19.1 (e.g., 19.1 ± 0.3 or 19.1 ± 0.2), about 19.8 (e.g., 19.8 ± 0.3 or 19.8 ± 0.2), about 20.9 (e.g., 20.9 ± 0.3 or 20.9 ± 0.2), and about 22.2 (e.g., 22.2 ± 0.3 or 22.2 ± 0.2) degrees 2-theta, and combinations thereof. In some embodiments, Form I has an XRPD pattern substantially as depicted in FIG. 1. In some embodiments, Form I exhibits a differential scanning calorimetry thermogram having an endotherm with an onset temperature of about 95 °C and a peak temperature of about 103 °C. In some embodiments, Form I exhibits a differential scanning calorimetry thermogram having an endotherm with an onset temperature of about 94.6 °C and 15 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 a peak temperature of about 103.1 °C. In some embodiments, Form I has an endothermic peak (e.g., a melting point) at a temperature of about 103 °C. In some embodiments, Form I has an exothermic peak at temperature about 187 °C. In some embodiments, Form I has a melting point of about 103.1 °C. In some embodiments, Form I has a DSC thermogram substantially as depicted in FIG. 2. In some embodiments, Form I has a TGA thermogram substantially as depicted in FIG. 3. In some embodiments, Form I exhibits a DSC thermogram having an endotherm with an onset temperature of about 95 °C, and a peak temperature of about 103 °C; and an X-ray powder diffraction pattern comprising one or more characteristic peaks at about 3.6, about 4.9, about 6.2, about 7.7, or about 22.7 degrees 2-theta. In some embodiments, Form I exhibits a DSC thermogram having an endothermic peak at about 103 °C; and an X-ray powder diffraction pattern comprising one or more characteristic peaks at about 3.6, about 4.9, about 6.2, about 7.7, or about 22.7 degrees 2-theta. In some embodiments, Form I exhibits a differential scanning calorimetry thermogram having an endotherm with an onset temperature of about 94.6 °C and a peak temperature of about 103.1 °C; and an X-ray powder diffraction pattern comprising a characteristic peak at about 3.6 (e.g., 3.6 ± 0.3 or 3.6 ± 0.2), about 4.9 (e.g., 4.9 ± 0.3 or 4.9 ± 0.2), about 6.2 (e.g., 6.2 ± 0.3 or 6.2 ± 0.2), about 7.7 (e.g., 7.7 ± 0.3 or 7.7 ± 0.2) or about 22.7 (e.g., 22.7 ± 0.3 or 22.7 ± 0.2) degrees 2-theta. In some embodiments, Form I exhibits a DSC thermogram having an exothermic peak at about 187 °C; and an X-ray powder diffraction pattern comprising one or more characteristic peaks at about 3.6, about 4.9, about 6.2, about 7.7, or about 22.7 degrees 2-theta. In some embodiments, Form I has an XRPD pattern substantially as depicted in FIG. 1 and a DSC thermogram substantially as depicted in FIG. 2. Form HI of Compound I di-tosylate salt In some embodiments, the present application relates to the crystalline form of Compound I di-tosylate salt referred to as Form HI, which is described below and in the Examples. The experimental evidence shows that Form HI is a hydrated form of Compound I di-tosylate salt. In some embodiments, Form HI has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, at about 7.0 degrees. In some embodiments, Form HI has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, at about 10.4 degrees. In some 16 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 embodiments, Form HI has an XRPD pattern comprising a characteristic peak, in terms of 2- theta, at about 13.6 degrees. In some embodiments, Form HI has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, at about 15.5 degrees. In some embodiments, Form HI has an XRPD pattern comprising a characteristic peak, in terms of 2- theta, at about 17.3 degrees. In some embodiments, Form HI has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, at about 22.2 degrees. In some embodiments, Form HI has an XRPD pattern comprising a characteristic peak, in terms of 2- theta, at about 24.0 degrees. In some embodiments, Form HI has an XRPD pattern comprising two or more characteristic peaks, in terms of 2-theta, selected from about 7.0, about 10.4, about 13.6, about 15.5, about 17.3, about 22.2, and about 24.0 degrees. In some embodiments, Form HI has an X-ray powder diffraction pattern comprising three or more characteristic peaks, in terms of 2-theta, selected from about 7.0, about 10.4, about 13.6, about 15.5, about 17.3, about 22.2, and about 24.0 degrees. In some embodiments, Form HI has an XRPD pattern comprising one or more characteristic peaks, in terms of 2-theta, selected from about 7.0, about 10.4, about 13.6, about 15.5, about 16.6, about 17.3, about 18.7, about 19.8, about 20.2, about 20.5, about 20.8, about 21.7, about 22.2, about 23.1, about 24.0, and about 28.2 degrees. In some embodiments, Form HI has an XRPD comprising two or more characteristic peaks, in terms of 2-theta, selected from about 7.0, about 10.4, about 13.6, about 15.5, about 16.6, about 17.3, about 18.7, about 19.8, about 20.2, about 20.5, about 20.8, about 21.7, about 22.2, about 23.1, about 24.0, and about 28.2 degrees. In some embodiments, Form HI has an XRPD pattern comprising three or more characteristic peaks, in terms of 2-theta, selected from about 7.0, about 10.4, about 13.6, about 15.5, about 16.6, about 17.3, about 18.7, about 19.8, about 20.2, about 20.5, about 20.8, about 21.7, about 22.2, about 23.1, about 24.0, and about 28.2 degrees. In some embodiments, Form HI has an XRPD pattern comprising four or more characteristic peaks, in terms of 2-theta, selected from about 7.0, about 10.4, about 13.6, about 15.5, about 16.6, about 17.3, about 18.7, about 19.8, about 20.2, about 20.5, about 20.8, about 21.7, about 22.2, about 23.1, about 24.0, and about 28.2 degrees. In some embodiments, Form HI has an XRPD pattern substantially as depicted in FIG. 4. 17 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 In some embodiments. Form HI exhibits a differential scanning calorimetry thermogram having an endotherm with an onset temperature of about 74 °C and a peak temperature of about 80 °C. In some embodiments, Form HI has an endothermic peak (e.g., a dehydration event) at a temperature of about 80 °C. In some embodiments, Form HI has a DSC thermogram substantially as depicted in FIG. 5. In some embodiments, Form HI has a TGA thermogram substantially as depicted in FIG. 6. In some embodiments, Form HI exhibits a differential scanning calorimetry thermogram having an endothermic peak at a temperature of about 80 °C; and an XRPD pattern comprising a characteristic peak selected from about 7.0, about 15.5, and about 17.3 degrees 2-theta. In some embodiments, Form HI exhibits a differential scanning calorimetry thermogram having an endotherm with an onset temperature of about 74 °C and a peak temperature of about 80 °C; and an XRPD pattern comprising a characteristic peak selected from about 7.0, about 15.5, and about 17.3 degrees 2-theta. In some embodiments, Form HI exhibits a differential scanning calorimetry thermogram having an endothermic peak at a temperature of about 80 °C; and an XRPD pattern comprising a characteristic peak selected from about 7.0, about 10.4, about 13.6, about 15.5, about 17.3, about 22.2, and about 24.0 degrees. In some embodiments, Form HI exhibits a differential scanning calorimetry thermogram having an endotherm with an onset temperature of about 74 °C and a peak temperature of about 80 °C; and an XRPD pattern comprising a characteristic peak selected from about 7.0, about 10.4, about 13.6, about 15.5, about 17.3, about 22.2, and about 24.0 degrees. In some embodiments, Form HI has an XRPD pattern substantially as depicted in FIG. 4 and a DSC thermogram substantially as depicted in FIG. 5. Form HII of Compound I di-tosylate salt In some embodiments, the present application relates to the crystalline form of Compound I di-tosylate salt referred to as Form HII, which is described below and in the Examples. The experimental evidence shows that Form HII is a hydrated form of Compound I di-tosylate salt. In some embodiments, Form HII has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, at about 8.7 degrees. In some embodiments, Form HII has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, at about 10.1 degrees. In some 18 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 embodiments, Form HII has an XRPD pattern comprising a characteristic peak, in terms of 2- theta, at about 14.8 degrees. In some embodiments, Form HII has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, at about 21.3 degrees. In some embodiments, Form HII has an XRPD pattern comprising a characteristic peak, in terms of 2- theta, at about 22.0 degrees. In some embodiments, Form HII has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, at about 22.7 degrees. In some embodiments, Form HII has an XRPD pattern comprising a characteristic peak, in terms of 2- theta, at about 24.3 degrees. In some embodiments, Form HII has an XRPD pattern comprising two or more characteristic peaks, in terms of 2-theta, selected from about 8.7, about 10.1, about 14.8, about 21.3, about 22.0, about 22.7, and about 24.3 degrees 2-theta. In some embodiments, Form HII has an XRPD pattern comprising three or more characteristic peaks, in terms of 2-theta, selected from about 8.7, about 10.1, about 14.8, about 21.3, about 22.0, about Tl.I , and about 24.3 degrees 2-theta. In some embodiments, Form HII has an X-ray powder diffraction pattern substantially as shown in FIG. 7. In some embodiments, Form HII exhibits a differential scanning calorimetry thermogram having an endothermic peak at a temperature of about 52 °C. In some embodiments, Form HII has a DSC thermogram substantially as depicted in FIG. 8. In some embodiments, Form HII has a TGA thermogram substantially as depicted in FIG. 9. In some embodiments, Form HII exhibits a differential scanning calorimetry thermogram having an endothermic peak at a temperature of about 52 °C; and an X-ray powder diffraction pattern comprising a characteristic peak selected from about 8.7, about 10.1, about 14.8, about 21.3, about 22.0, about 22.7, and about 24.3 degrees 2-theta. In some embodiments, Form HII has an XRPD pattern substantially as depicted in FIG. 7 and a DSC thermogram substantially as depicted in FIG. 8. Form Hill of Compound I di-tosylate salt In some embodiments, the present application relates to the crystalline form of Compound I di-tosylate salt referred to as Form Hill, which is described below and in the 19 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 Examples. The experimental evidence shows Form Hill is a hydrated form of Compound I di-tosylate salt. In some embodiments. Form Hill has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, at about 7.0 degrees. In some embodiments, Form Hill has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, at about 9.0 degrees. In some embodiments, Form Hill has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, at about 9.2 degrees. In some embodiments, Form Hill has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, at about 10.2 degrees. In some embodiments, Form Hill has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, at about 17.9 degrees. In some embodiments, Form Hill has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, at about 20.3 degrees. In some embodiments, Form Hill has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, at about 22.0 degrees. In some embodiments, Form Hill has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, at about 23.8 degrees. In some embodiments, Form Hill has an XRPD pattern comprising two or more characteristic peaks, in terms of 2-theta, selected from about 7.0, about 9.0, about 9.2, about 10.2, about 17.9, about 20.3, about 22.0, and about 23.8 degrees. In some embodiments, Form Hill has an XRPD pattern comprising three or more characteristic peaks, in terms of 2-theta, selected from about 7.0, about 9.0, about 9.2, about 10.2, about 17.9, about 20.3, about 22.0, and about 23.8 degrees 2-theta. In some embodiments, Form Hill has an X-ray powder diffraction pattern substantially as shown in FIG. 10. In some embodiments, Form Hill exhibits a differential scanning calorimetry thermogram having an endothermic peak at a temperature of about 67 °C. In some embodiments, Form Hill further exhibits an endothermic peak at a temperature of about 98 °C. In some embodiments, Form Hill has a DSC thermogram substantially as depicted in FIG. 11. In some embodiments, Form Hill has a TGA thermogram substantially as depicted in FIG. 12. In some embodiments, Form Hill exhibits a differential scanning calorimetry thermogram having endothermic peaks at temperatures of about 67 °C and about 98 °C; and 20 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 an X-ray powder diffraction pattern comprising a characteristic peak selected from about 7.0, about 9.0, about 9.2, about 10.2, about 17.9, about 20.3, about 22.0, and about 23.8 degrees 2-theta. In some embodiments, Form Hill has an XRPD pattern substantially as depicted in FIG. 10 and a DSC thermogram substantially as depicted in FIG. 11. Form DH of Compound! di-tosylate salt In some embodiments, the present application relates to the crystalline form of Compound I di-tosylate salt referred to as Form DH, which is described below and in the Examples. In some embodiments, Form DH has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, at about 7.5 degrees. In some embodiments, Form DH has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, at about 9.6 degrees. In some embodiments, Form DH has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, at about 10.7 degrees. In some embodiments, FormDH has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, at about 14.8 degrees. In some embodiments, Form DH has an XRPD pattern comprising a characteristic peak, in terms of 2- theta, at about 20.1 degrees. In some embodiments, Form DH has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, at about 20.7 degrees. In some embodiments, Form DH has an XRPD pattern comprising a characteristic peak, in terms of 2- theta, at about 21.6 degrees. In some embodiments, Form DH has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, at about 22.9 degrees. In some embodiments, Form DH has an XRPD pattern comprising a characteristic peak, in terms of 2- theta, at about 24.7 degrees. In some embodiments, Form DH has an XRPD pattern comprising two or more characteristic peaks, in terms of 2-theta, selected from about 7.5, about 9.6, about 10.7, about 14.8, about 20.1, about 20.7, about 21.6, about 22.9, and about 24.7 degrees 2-theta. In some embodiments, Form DH has an XRPD pattern comprising three or more characteristic peaks, in terms of 2-theta, selected from about 7.5, about 9.6, about 10.7, about 14.8, about 20.1, about 20.7, about 21.6, about 22.9, and about 24.7 degrees 2-theta. In some embodiments, Form DH has an X-ray powder diffraction pattern substantially as shown in FIG. 13. 21 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 In some embodiments. Form DH exhibits a differential scanning calorimetry thermogram having an endothermic peak at a temperature of about 98 °C. In some embodiments. Form DH has a DSC thermogram substantially as depicted in FIG. 14. In some embodiments, Form DH has a TGA thermogram substantially as depicted in FIG. 15. In some embodiments, Form DH exhibits a differential scanning calorimetry thermogram having an endothermic peak at a temperature of about 98 °C; and an X-ray powder diffraction pattern comprising a characteristic peak selected from about 7.5, about 9.6, about 10.7, about 14.8, about 20.1, about 20.7, about 21.6, about 22.9, and about 24.7 degrees 2-theta. In some embodiments, Form DH has an XRPD pattern substantially as depicted in FIG. 13 and a DSC thermogram substantially as depicted in FIG. 14. Form II of Compound I di-tosylate salt In some embodiments, the present application relates to the crystalline form of Compound I di-tosylate salt referred to as Form II, which is described below and in the Examples. In some embodiments, Form II has an XRPD pattern comprising a characteristic peak, in terms of 2-1heta, at about 6.8 degrees. In some embodiments, Form II has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, selected from about 5.1, about 6.8, and about 10.2 degrees. In some embodiments, Form II has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, selected from about 5.1, about 6.8, about 10.2, about 14.3, about 15.8, about 17.7, and about 23.3 degrees. In some embodiments, Form II has an XRPD pattern comprising two or more characteristic peaks, in terms of 2-theta, selected from about 5.1, about 6.8, about 10.2, about 14.3, about 15.8, about 17.7, and about 23.3 degrees. In some embodiments, Form II has an X-ray powder diffraction pattern comprising three or more characteristic peaks, in terms of 2-theta, selected from about 5.1, about 6.8, about 10.2, about 14.3, about 15.8, about 17.7, and about 23.3 degrees. In some embodiments, Form II has an XRPD pattern comprising one or more characteristic peaks, in terms of 2-theta, selected from about 5.1, about 6.8, about 10.2, about 14.2, about 15.8, about 17.7, about 20.4, about 23.3, about 24.3, and about 26.9 degrees. 22 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 In some embodiments. Form II has an XRPD comprising two or more characteristic peaks, in terms of 2-theta, selected from about 5.1, about 6.8, about 10.2, about 14.2, about 15.8, about 17.7, about 20.4, about 23.3, about 24.3, and about 26.9 degrees. In some embodiments, Form II has an XRPD pattern comprising three or more characteristic peaks, in terms of 2-theta, selected from about 5.1, about 6.8, about 10.2, about 14.2, about 15.8, about 17.7, about 20.4, about 23.3, about 24.3, and about 26.9 degrees. In some embodiments, Form II has an XRPD pattern comprising four or more characteristic peaks, in terms of 2-theta, selected from about 5.1, about 6.8, about 10.2, about 14.2, about 15.8, about 17.7, about 20.4, about 23.3, about 24.3, and about 26.9 degrees. In some embodiments, Form II has an XRPD pattern substantially as depicted in FIG. 19. In some embodiments, Form II exhibits a differential scanning calorimetry thermogram having an endothermic peak at a temperature of about 78 °C. In some embodiments. Form II has an exothermic peak at a temperature of about 185 °C. In some embodiments, Form II exhibits a differential scanning calorimetry thermogram having an endothermic peak at a temperature of about 78 °C and an exothermic peak at a temperature of about 185 °C. In some embodiments, Form II has a DSC thermogram substantially as depicted in FIG. 20. In some embodiments, Form II has a TGA thermogram substantially as depicted in FIG. 21. Form III of Compound I di-tosylate salt In some embodiments, the present application relates to the crystalline form of Compound I di-tosylate salt referred to as Form III, which is described below and in the Examples. In some embodiments, Form III has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, at about 4.6 degrees. In some embodiments, Form III has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, selected from about 4.6 and about 5.2 degrees. In some embodiments, Form III has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, selected from about 4.6, about 5.2, about 6.4, about 9.2, about 22.8, and about 24.2 degrees. 23 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 In some embodiments. Form III has an XRPD pattern comprising two or more characteristic peaks, in terms of 2-theta, selected from about 4.6, about 5.2, about 6.4, about 9.2, about 22.8, and about 24.2 degrees. In some embodiments, Form III has an X-ray powder diffraction pattern comprising three or more characteristic peaks, in terms of 2-theta, selected from about 4.6, about 5.2, about 6.4, about 9.2, about 22.8, and about 24.2 degrees. In some embodiments, Form III has an XRPD pattern comprising one or more characteristic peaks, in terms of 2-theta, selected from about 4.6, about 5.2, about 6.4, about 9.2, about 14.0, about 16.3, about 18.4, about 22.8, and about 24.2 degrees. In some embodiments, Form III has an XRPD comprising two or more characteristic peaks, in terms of 2-theta, selected from about 4.6, about 5.2, about 6.4, about 9.2, about 14.0, about 16.3, about 18.4, about 22.8, and about 24.2 degrees. In some embodiments, Form III has an XRPD pattern comprising three or more characteristic peaks, in terms of 2-theta, selected from about 4.6, about 5.2, about 6.4, about 9.2, about 14.0, about 16.3, about 18.4, about 22.8, and about 24.2 degrees. In some embodiments, Form III has an XRPD pattern comprising four or more characteristic peaks, in terms of 2-theta, selected from about 4.6, about 5.2, about 6.4, about 9.2, about 14.0, about 16.3, about 18.4, about 22.8, and about 24.2 degrees. In some embodiments, Form III has an XRPD pattern substantially as depicted in FIG. 22. In some embodiments, Form III exhibits a differential scanning calorimetry thermogram having an endothermic peak at a temperature of about 80 °C. In some embodiments, Form III has an exothermic peak at a temperature of about 181 °C. In some embodiments, Form III exhibits a differential scanning calorimetry thermogram having an endothermic peak at a temperature of about 80 °C and an exothermic peak at a temperature of about 181 °C. In some embodiments, Form III has a DSC thermogram substantially as depicted in FIG. 23. In some embodiments, Form III has a TGA thermogram substantially as depicted in FIG. 24. Form Illa of Compound I di-tosylate salt 24 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 In some embodiments, the present application relates to the crystalline form of Compound I di-tosylate salt referred to as Form Illa, which is described below and in the Examples. In some embodiments, Form Illa has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, selected from about 4.5, about 5.1, and about 6.9 degrees. In some embodiments, Form Illa has an XRPD pattern comprising a characteristic peak, in terms of 2- theta, selected from about 4.5, about 5.1, about 6.9, about 8.1, about 10.1, about 22.7, and about 24.1 degrees. In some embodiments, Form Illa has an XRPD pattern comprising two or more characteristic peaks, in terms of 2-theta, selected from about 4.5, about 5.1, about 6.9, about 8.1, about 10.1, about 22.7, and about 24.1 degrees. In some embodiments, Form Illa has an X-ray powder diffraction pattern comprising three or more characteristic peaks, in terms of 2-theta, selected from about 4.5, about 5.1, about 6.9, about 8.1, about 10.1, about 22.7, and about 24.1 degrees. In some embodiments, Form Illa has an XRPD pattern comprising one or more characteristic peaks, in terms of 2-theta, selected from about 4.5, about 5.1, about 6.9, about 8.1, about 10.1, about 16.3, about 20.8, about 22.7, and about 24.1 degrees. In some embodiments, Form Illa has an XRPD pattern comprising two or more characteristic peaks, in terms of 2-theta, selected from about 4.5, about 5.1, about 6.9, about 8.1, about 10.1, about 16.3, about 20.8, about 22.7, and about 24.1 degrees. In some embodiments, Form Illa has an X-ray powder diffraction pattern comprising three or more characteristic peaks, in terms of 2-theta, selected from about 4.5, about 5.1, about 6.9, about 8.1, about 10.1, about 16.3, about 20.8, about 22.7, and about 24.1 degrees. In some embodiments, Form Illa has an XRPD pattern substantially as depicted in FIG. 25. Form IV of Compound I di-tosylate salt In some embodiments, the present application relates to the crystalline form of Compound I di-tosylate salt referred to as Form IV, which is described below and in the Examples. In some embodiments, Form IV has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, at about 7.1 degrees. In some embodiments, Form IV has an XRPD 25 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 pattern comprising a characteristic peak, in terms of 2-theta, selected from about 7.1, about 8.9, and about 10.5 degrees. In some embodiments, Form IV has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, selected from about 7.1, about 8.9, about 10.5, about 14.6, and about 18.0 degrees. In some embodiments, Form IV has an XRPD pattern comprising two or more characteristic peaks, in terms of 2-theta, selected from about 7.1, about 8.9, about 10.5, about 14.6, and about 18.0 degrees. In some embodiments, Form IV has an X-ray powder diffraction pattern comprising three or more characteristic peaks, in terms of 2-theta, selected from about 7.1, about 8.9, about 10.5, about 14.6, and about 18.0 degrees. In some embodiments, Form IV has an XRPD pattern comprising one or more characteristic peaks, in terms of 2-theta, selected from about 7.1, about 8.9, about 10.5, about 14.6, about 18.0, about 20.1, about 23.1, and about 24.8 degrees. In some embodiments, Form IV has an XRPD comprising two or more characteristic peaks, in terms of 2-theta, selected from about 7.1, about 8.9, about 10.5, about 14.6, about 18.0, about 20.1, about 23.1, and about 24.8 degrees. In some embodiments, Form IV has an XRPD pattern comprising three or more characteristic peaks, in terms of 2-theta, selected from about 7.1, about 8.9, about 10.5, about 14.6, about 18.0, about 20.1, about 23.1, and about 24.8 degrees. In some embodiments, Form IV has an XRPD pattern comprising four or more characteristic peaks, in terms of 2-theta, selected from about 7.1, about 8.9, about 10.5, about 14.6, about 18.0, about 20.1, about 23.1, and about 24.8 degrees. In some embodiments, Form IV has an XRPD pattern substantially as depicted in FIG. 26. In some embodiments, Form IV exhibits a differential scanning calorimetry thermogram having an endothermic peak at a temperature of about 54 °C. In some embodiments. Form IV has an endothermic peak at a temperature of about 125 °C. In some embodiments. Form IV has an exothermic peak at a temperature of about 171 °C. In some embodiments, Form IV has endothermic peaks at temperatures of about 54 °C and about 125 °C and an exothermic peak at a temperature of about 171 °C. In some embodiments, Form IV has a DSC thermogram substantially as depicted in FIG. 27. In some embodiments, Form IV has a TGA thermogram substantially as depicted in FIG. 28. 26 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 Form IVa of Compound I di-tosylate salt In some embodiments, the present application relates to the crystalline form of Compound I di-tosylate salt referred to as Form IVa, which is described below and in the Examples. In some embodiments, Form IVa has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, at about 6.9 degrees. In some embodiments, Form IVa has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, selected from about 6.4, about 6.9, and about 10.5 degrees. In some embodiments, Form IVa has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, selected from about 6.4, about 6.9, about 8.7, about 10.1, and about 14.4 degrees. In some embodiments, Form IVa has an XRPD pattern comprising two or more characteristic peaks, in terms of 2-theta, selected from about 6.4, about 6.9, about 8.7, about 10.1, and about 14.4 degrees. In some embodiments, Form IVa has an X-ray powder diffraction pattern comprising three or more characteristic peaks, in terms of 2-theta, selected from about 6.4, about 6.9, about 8.7, about 10.1, and about 14.4 degrees. In some embodiments, Form IVa has an XRPD pattern comprising one or more characteristic peaks, in terms of 2-theta, selected from about 6.4, about 6.9, about 8.7, about 10.1, about 14.4, about 22.1, about 22.8, about 24.4, about 24.7, and about 28.5 degrees. In some embodiments, Form IVa has an XRPD comprising two or more characteristic peaks, in terms of 2-theta, selected from about 6.4, about 6.9, about 8.7, about 10.1, about 14.4, about 22.1, about 22.8, about 24.4, about 24.7, and about 28.5 degrees. In some embodiments, Form IVa has an XRPD pattern comprising three or more characteristic peaks, in terms of 2-theta, selected from about 6.4, about 6.9, about 8.7, about 10.1, about 14.4, about 22.1, about 22.8, about 24.4, about 24.7, and about 28.5 degrees. In some embodiments, Form IVa has an XRPD pattern comprising four or more characteristic peaks, in terms of 2-theta, selected from about 6.4, about 6.9, about 8.7, about 10.1, about 14.4, about 22.1, about 22.8, about 24.4, about 24.7, and about 28.5 degrees. In some embodiments, Form IVa has an XRPD pattern substantially as depicted in FIG. 29. 27 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 In some embodiments. Form IVa exhibits a differential scanning calorimetry thermogram having an endothermic peak at a temperature of about 53 °C. In some embodiments. Form IVa has an exothermic peak at a temperature of about 183 °C. In some embodiments, Form IVa exhibits a differential scanning calorimetry thermogram having an endothermic peak at a temperature of about 53 °C and an exothermic peak at a temperature of about 183 °C. In some embodiments, Form IVa has a DSC thermogram substantially as depicted in FIG. 30. In some embodiments, Form IVa has a TGA thermogram substantially as depicted in FIG. 31. Form V of Compound I di-tosylate salt In some embodiments, the present application relates to the crystalline form of Compound I di-tosylate salt referred to as Form V, which is described below and in the Examples. In some embodiments, Form V has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, at about 7.3 degrees. In some embodiments, Form V has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, selected from about 5.6, about 7.3, and about 10.3 degrees. In some embodiments, Form V has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, selected from about 5.6, about 7.3, about 10.8, about 16.7, about 17.6, and about 21.2 degrees. In some embodiments, Form V has an XRPD pattern comprising two or more characteristic peaks, in terms of 2-theta, selected from about 5.6, about 7.3, about 10.8, about 16.7, about 17.6, and about 21.2 degrees. In some embodiments, Form V has an X-ray powder diffraction pattern comprising three or more characteristic peaks, in terms of 2-theta, selected from about 5.6, about 7.3, about 10.8, about 16.7, about 17.6, and about 21.2 degrees. In some embodiments, Form V has an XRPD pattern comprising one or more characteristic peaks, in terms of 2-theta, selected from about 5.6, about 7.3, about 10.8, about 16.7, about 17.6, about 20.1, about 21.2, about 23.3, and about 24.3 degrees. In some embodiments, Form V has an XRPD comprising two or more characteristic peaks, in terms of 2-theta, selected from about 5.6, about 7.3, about 10.8, about 16.7, about 17.6, about 20.1, about 21.2, about 23.3, and about 24.3 degrees. 28 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 In some embodiments. Form V has an XRPD pattern comprising three or more characteristic peaks, in terms of 2-theta, selected from about 5.6, about 7.3, about 10.8, about 16.7, about 17.6, about 20.1, about 21.2, about 23.3, and about 24.3 degrees. In some embodiments, Form V has an XRPD pattern comprising four or more characteristic peaks, in terms of 2-theta, selected from about 5.6, about 7.3, about 10.8, about 16.7, about 17.6, about 20.1, about 21.2, about 23.3, and about 24.3 degrees. In some embodiments, Form V has an XRPD pattern substantially as depicted in FIG. 32. In some embodiments, Form V exhibits a differential scanning calorimetry thermogram having an endothermic peak at a temperature of about 53 °C. In some embodiments, Form V exhibits a differential scanning calorimetry thermogram having an endothermic peak at a temperature of about 83 °C. In some embodiments, Form V has an exothermic peak at a temperature of about 185 °C. In some embodiments, Form V exhibits a differential scanning calorimetry thermogram having endothermic peaks at temperatures of about 53 °C and about 83 °C and an exothermic peak at a temperature of about 185 °C. In some embodiments, Form V has a DSC thermogram substantially as depicted in FIG. 33. In some embodiments, Form V has a TGA thermogram substantially as depicted in FIG. 34. Form VI of Compound I di-tosylate salt In some embodiments, the present application relates to the crystalline form of Compound I di-tosylate salt referred to as Form VI, which is described below and in the Examples. In some embodiments, Form VI has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, selected from about 7.4, about 10.9, and about 14.1 degrees. In some embodiments, Form VI has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, selected from about 7.4, about 10.9, about 14.1, about 16.0, about 17.1, and about 17.4 degrees. In some embodiments, Form VI has an XRPD pattern comprising two or more characteristic peaks, in terms of 2-theta, selected from about 7.4, about 10.9, about 14.1, about 16.0, about 17.1, and about 17.4 degrees. 29 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 In some embodiments. Form VI has an X-ray powder diffraction pattern comprising three or more characteristic peaks, in terms of 2-theta, selected from about 7.4, about 10.9, about 14.1, about 16.0, about 17.1, and about 17.4 degrees. In some embodiments, Form VI has an XRPD pattern comprising one or more characteristic peaks, in terms of 2-theta, selected from about 7.4, about 10.9, about 14.1, about 16.0, about 17.1, about 17.4, about 22.8, about 23.5, and about 24.5 degrees. In some embodiments, Form VI has an XRPD comprising two or more characteristic peaks, in terms of 2-theta, selected from about 7.4, about 10.9, about 14.1, about 16.0, about 17.1, about 17.4, about 22.8, about 23.5, and about 24.5 degrees. In some embodiments, Form VI has an XRPD pattern comprising three or more characteristic peaks, in terms of 2-theta, selected from about 7.4, about 10.9, about 14.1, about 16.0, about 17.1, about 17.4, about 22.8, about 23.5, and about 24.5 degrees. In some embodiments, Form VI has an XRPD pattern comprising four or more characteristic peaks, in terms of 2-theta, selected from about 7.4, about 10.9, about 14.1, about 16.0, about 17.1, about 17.4, about 22.8, about 23.5, and about 24.5 degrees. In some embodiments, Form VI has an XRPD pattern substantially as depicted in FIG. 35. In some embodiments, Form VI exhibits a differential scanning calorimetry thermogram having an endothermic peak at a temperature of about 82 °C. In some embodiments, Form VI has an exothermic peak at a temperature of about 185 °C. In some embodiments, Form VI exhibits a differential scanning calorimetry thermogram having an endothermic peak at a temperature of about 82 °C and an exothermic peak at a temperature of about 185 °C. In some embodiments, Form VI has a DSC thermogram substantially as depicted in FIG. 36. In some embodiments, Form VI has a TGA thermogram substantially as depicted in FIG. 37. Form VII of Compound I di-tosylate salt In some embodiments, the present application relates to the crystalline form of Compound I di-tosylate salt referred to as Form VII, which is described below and in the Examples. 30 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 In some embodiments. Form VII has an XRPD pattern comprising a characteristic peaks, in terms of 2-theta, selected from about 17.2, about 21.6, about 23.0, about 23.8, about 24.8, and about 26.0 degrees. In some embodiments, Form VII has an XRPD pattern comprising two or more characteristic peaks, in terms of 2-theta, selected from about 17.2, about 21.6, about 23.0, about 23.8, about 24.8, and about 26.0 degrees. In some embodiments, Form VII has an X-ray powder diffraction pattern comprising three or more characteristic peaks, in terms of 2-theta, selected from about 17.2, about 21.6, about 23.0, about 23.8, about 24.8, and about 26.0degrees. In some embodiments, Form VII has an XRPD pattern comprising four or more characteristic peaks, in terms of 2-theta, selected from about 17.2, about 21.6, about 23.0, about 23.8, about 24.8, and about 26.0 degrees. In some embodiments, Form VII has an XRPD pattern substantially as depicted in FIG. 38. In some embodiments, Form VII exhibits a differential scanning calorimetry thermogram having an endothermic peak at a temperature of about 90 °C. In some embodiments, Form VII has an exothermic peak at a temperature of about 185 °C. In some embodiments, Form VII exhibits a differential scanning calorimetry thermogram having an endothermic peak at a temperature of about 90 °C and an exothermic peak at a temperature of about 185 °C. In some embodiments, Form VII has a DSC thermogram substantially as depicted in FIG. 39. In some embodiments, Form VII has a TGA thermogram substantially as depicted in FIG. 40. Form VIII of Compound I di-tosylate salt In some embodiments, the present application relates to the crystalline form of Compound I di-tosylate salt referred to as Form VIII, which is described below and in the Examples. In some embodiments, Form VIII has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, at about 7.2 degrees. In some embodiments, Form Vin has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, selected from about 7.2, about 10.6, about 14.7, and about 16.3 degrees. In some embodiments, Form VIII has an 31 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 XRPD pattern comprising a characteristic peak, in terms of 2-theta, selected from about 7.2, about 10.6, about 14.7, about 16.3, and about 23.8 degrees. In some embodiments, Form VIII has an XRPD pattern comprising two or more characteristic peaks, in terms of 2-theta, selected from about 7.2, about 10.6, about 14.7, about 16.3, and about 23.8 degrees. In some embodiments, Form VIII has an X-ray powder diffraction pattern comprising three or more characteristic peaks, in terms of 2-theta, selected from about 7.2, about 10.6, about 14.7, about 16.3, and about 23.8 degrees. In some embodiments, Form VIII has an XRPD pattern comprising one or more characteristic peaks, in terms of 2-theta, selected from about 7.2, about 10.6, about 14.7, about 16.3, about 17.5, about 18.1, about 20.7, about 21.5, about 22.9, about 23.8, about 24.8, and about 27.4 degrees. In some embodiments, Form VIII has an XRPD comprising two or more characteristic peaks, in terms of 2-theta, selected from about 7.2, about 10.6, about 14.7, about 16.3, about 17.5, about 18.1, about 20.7, about 21.5, about 22.9, about 23.8, about 24.8, and about 27.4 degrees. In some embodiments, Form VIII has an XRPD pattern comprising three or more characteristic peaks, in terms of 2-theta, selected from about 7.2, about 10.6, about 14.7, about 16.3, about 17.5, about 18.1, about 20.7, about 21.5, about 22.9, about 23.8, about 24.8, and about 27.4 degrees. In some embodiments, Form VIII has an XRPD pattern comprising four or more characteristic peaks, in terms of 2-theta, selected from about 7.2, about 10.6, about 14.7, about 16.3, about 17.5, about 18.1, about 20.7, about 21.5, about 22.9, about 23.8, about 24.8, and about 27.4 degrees. In some embodiments, Form VIII has an XRPD pattern substantially as depicted in FIG. 41. In some embodiments, Form VIII exhibits a differential scanning calorimetry thermogram having an endothermic peak at a temperature of about 75 °C. In some embodiments, Form VIII has an exothermic peak at a temperature of about 186 °C. In some embodiments, Form VIII exhibits a differential scanning calorimetry thermogram having an endothermic peak at a temperature of about 75 °C and an exothermic peak at a temperature of about 186 °C. In some embodiments, Form VIII has a DSC thermogram substantially as 32 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 depicted in FIG. 42. In some embodiments. Form VIII has a TGA thermogram substantially as depicted in FIG. 43. Form IX of Compound I di-tosylate salt In some embodiments, the present application relates to the crystalline form of Compound I di-tosylate salt referred to as Form IX, which is described below and in the Examples. In some embodiments, Form IX has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, at about 5.3 degrees. In some embodiments, Form IX has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, selected from about 5.3, about 10.5, about 15.7, and about 16.3 degrees. In some embodiments, Form IX has an XRPD pattern comprising two or more characteristic peaks, in terms of 2-theta, selected from about 5.3, about 10.5, about 15.7, and about 16.3 degrees. In some embodiments, Form IX has an X-ray powder diffraction pattern comprising three or more characteristic peaks, in terms of 2-theta, selected from about 5.3, about 10.5, about 15.7, and about 16.3 degrees. In some embodiments, Form IX has an XRPD pattern comprising one or more characteristic peaks, in terms of 2-theta, selected from about 5.3, about 10.5, about 15.7, about 16.3, about 21.0, about 21.4, and about 26.7 degrees. In some embodiments, Form IX has an XRPD comprising two or more characteristic peaks, in terms of 2-theta, selected from about 5.3, about 10.5, about 15.7, about 16.3, about 21.0, about 21.4, and about 26.7 degrees. In some embodiments, Form IX has an XRPD pattern comprising three or more characteristic peaks, in terms of 2-theta, selected from about 5.3, about 10.5, about 15.7, about 16.3, about 21.0, about 21.4, and about 26.7 degrees. In some embodiments, Form IX has an XRPD pattern comprising four or more characteristic peaks, in terms of 2-theta, selected from about 5.3, about 10.5, about 15.7, about 16.3, about 21.0, about 21.4, and about 26.7 degrees. In some embodiments, Form IX has an XRPD pattern substantially as depicted in FIG. 44. 33 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 In some embodiments. Form IX exhibits a differential scanning calorimetry thermogram having an endothermic peak at a temperature of about 82 °C. In some embodiments. Form IX has an exothermic peak at a temperature of about 186 °C. In some embodiments, Form IX exhibits a differential scanning calorimetry thermogram having an endothermic peak at a temperature of about 82 °C and an exothermic peak at a temperature of about 186 °C. In some embodiments, Form IX has a DSC thermogram substantially as depicted in FIG. 45. In some embodiments, Form IX has a TGA thermogram substantially as depicted in FIG. 46. Form X of Compound I di-tosylate salt In some embodiments, the present application relates to the crystalline form of Compound I di-tosylate salt referred to as Form X, which is described below and in the Examples. In some embodiments, Form X has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, selected from about 5.3, about 6.9, about 10.4, and about 14.5 degrees. In some embodiments, Form X has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, selected from about 5.3, about 6.9, about 10.4, about 14.5, about 16.4, and about 18.0 degrees. In some embodiments, Form X has an XRPD pattern comprising two or more characteristic peaks, in terms of 2-theta, selected from about 5.3, about 6.9, about 10.4, about 14.5, about 16.4, and about 18.0 degrees. In some embodiments, Form X has an X-ray powder diffraction pattern comprising three or more characteristic peaks, in terms of 2-theta, selected from about 5.3, about 6.9, about 10.4, about 14.5, about 16.4, and about 18.0 degrees. In some embodiments, Form X has an XRPD pattern comprising one or more characteristic peaks, in terms of 2-theta, selected from about 5.3, about 6.9, about 10.4, about 14.5, about 16.4, about 18.0, about 20.8, and about 24.0 degrees. In some embodiments, Form X has an XRPD comprising two or more characteristic peaks, in terms of 2-theta, selected from about 5.3, about 6.9, about 10.4, about 14.5, about 16.4, about 18.0, about 20.8, and about 24.0 degrees. 34 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 In some embodiments. Form X has an XRPD pattern comprising three or more characteristic peaks, in terms of 2-theta, selected from about 5.3, about 6.9, about 10.4, about 14.5, about 16.4, about 18.0, about 20.8, and about 24.0 degrees. In some embodiments, Form X has an XRPD pattern comprising four or more characteristic peaks, in terms of 2-theta, selected from about 5.3, about 10.5, about 15.7, about 16.3, about 21.0, about 21.4, and about 26.7 degrees. In some embodiments, Form X has an XRPD pattern substantially as depicted in FIG. 47. In some embodiments, Form X exhibits a differential scanning calorimetry thermogram having an endothermic peak at a temperature of about 79 °C. In some embodiments, Form X has an exothermic peak at a temperature of about 185 °C. hi some embodiments, Form X exhibits a differential scanning calorimetry thermogram having an endothermic peak at a temperature of about 79 °C and an exothermic peak at a temperature of about 185 °C. In some embodiments, Form X has a DSC thermogram substantially as depicted in FIG. 48. In some embodiments, Form X has a TGA thermogram substantially as depicted in FIG. 49. Form XI of Compound I di-tosylate salt In some embodiments, the present application relates to the crystalline form of Compound I di-tosylate salt referred to as Form XI, which is described below and in the Examples. In some embodiments, Form XI has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, at about 5.4 degrees. In some embodiments, Form XI has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, selected from about 5.4, about 6.7, about 15.5, about 16.1, and about 20.7 degrees. In some embodiments, Form XI has an XRPD pattern comprising two or more characteristic peaks, in terms of 2-theta, selected from about 5.4, about 6.7, about 15.5, about 16.1, and about 20.7 degrees. In some embodiments, Form XI has an X-ray powder diffraction pattern comprising three or more characteristic peaks, in terms of 2-theta, selected from about 5.4, about 6.7, about 15.5, about 16.1, and about 20.7 degrees. 35 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 In some embodiments. Form XI has an XRPD pattern comprising one or more characteristic peaks, in terms of 2-theta, selected from about 5.4, about 6.7, about 15.5, about 16.1, about 20.7, about 21.1, about 22.5, and about 23.4 degrees. In some embodiments, Form XI has an XRPD comprising two or more characteristic peaks, in terms of 2-theta, selected from about 5.4, about 6.7, about 15.5, about 16.1, about 20.7, about 21.1, about 22.5, and about 23.4 degrees. In some embodiments, Form XI has an XRPD pattern comprising three or more characteristic peaks, in terms of 2-theta, selected from about 5.4, about 6.7, about 15.5, about 16.1, about 20.7, about 21.1, about 22.5, and about 23.4 degrees. In some embodiments, Form XI has an XRPD pattern comprising four or more characteristic peaks, in terms of 2-theta, selected from about 5.4, about 6.7, about 15.5, about 16.1, about 20.7, about 21.1, about 22.5, and about 23.4 degrees. In some embodiments, Form XI has an XRPD pattern substantially as depicted in FIG. 50. In some embodiments, Form XI exhibits a differential scanning calorimetry thermogram having an endothermic peak at a temperature of about 82 °C. In some embodiments, Form XI has an exothermic peak at a temperature of about 186 °C. In some embodiments, Form XI exhibits a differential scanning calorimetry thermogram having an endothermic peak at a temperature of about 82 °C and an exothermic peak at a temperature of about 186 °C. In some embodiments, Form XI has a DSC thermogram substantially as depicted in FIG. 51. In some embodiments, Form XI has a TGA thermogram substantially as depicted in FIG. 52. Form XII of Compound I di-tosylate salt In some embodiments, the present application relates to the crystalline form of Compound I di-tosylate salt referred to as Form XII, which is described below and in the Examples. In some embodiments, Form XII has an XRPD pattern comprising a characteristic peak, in terms of 2-theta, selected from about 5.1 and about 6.8 degrees. In some embodiments, Form XII has an XRPD pattern comprising a characteristic peak, in terms of 2- theta, selected from about 5.1, about 6.8, about 8.8, about 10.2, about 9.2, and about 13.5 degrees. In some embodiments, Form XII has an XRPD pattern comprising a characteristic 36 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 peak, in terms of 2-theta, selected from about 5.1, about 6.8, about 8.8, about 9.2, about 10.2, about 13.5, about 15.4, about 16.5, and about 17.2 degrees. In some embodiments, Form XII has an XRPD pattern comprising two or more characteristic peaks, in terms of 2-theta, selected from about 5.1, about 6.8, about 8.8, about 9.2, about 10.2, about 13.5, about 15.4, about 16.5, and about 17.2 degrees. In some embodiments, Form XII has an X-ray powder diffraction pattern comprising three or more characteristic peaks, in terms of 2-theta, selected from about 5.1, about 6.8, about 8.8, about 9.2, about 10.2, about 13.5, about 15.4, about 16.5, and about 17.2 degrees. In some embodiments, Form XII has an XRPD pattern comprising one or more characteristic peaks, in terms of 2-theta, selected from about 5.1, about 6.8, about 8.8, about 9.2, about 10.2, about 13.5, about 15.4, about 16.5, about 17.2, about 20.8, about 22.1, and about 23.9 degrees. In some embodiments, Form XII has an XRPD comprising two or more characteristic peaks, in terms of 2-theta, selected from about 5.1, about 6.8, about 8.8, about 9.2, about 10.2, about 13.5, about 15.4, about 16.5, about 17.2, about 20.8, about 22.1, and about 23.9 degrees. In some embodiments, Form XII has an XRPD pattern comprising three or more characteristic peaks, in terms of 2-theta, selected from about 5.1, about 6.8, about 8.8, about 9.2, about 10.2, about 13.5, about 15.4, about 16.5, about 17.2, about 20.8, about 22.1, and about 23.9 degrees. In some embodiments, Form XII has an XRPD pattern comprising four or more characteristic peaks, in terms of 2-theta, selected from about 5.1, about 6.8, about 8.8, about 9.2, about 10.2, about 13.5, about 15.4, about 16.5, about 17.2, about 20.8, about 22.1, and about 23.9 degrees. In some embodiments, Form XII has an XRPD pattern substantially as depicted in FIG. 53. In some embodiments, Form XII exhibits a differential scanning calorimetry thermogram having an endothermic peak at a temperature of about 81 °C. In some embodiments, Form XI has an exothermic peak at a temperature of about 186 °C. In some embodiments, Form XII exhibits a differential scanning calorimetry thermogram having an endothermic peak at a temperature of about 81 °C and an exothermic peak at a temperature of about 186 °C. In 37 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 some embodiments, Form XI has a DSC thermogram substantially as depicted in FIG. 54. In some embodiments, Form XI has a TGA thermogram substantially as depicted in FIG. 55. The salts and compounds disclosed herein can include all isotopes of atoms occurring in the intermediate or final compounds or salts. Isotopes include those atoms having the same atomic number but different mass numbers. For example, isotopes of hydrogen include tritium and deuterium. One or more constituent atoms of the salts or compounds of the invention can be replaced or substituted with isotopes of the atoms in natural or non-natural abundance. In some embodiments, the salt or compound includes at least one deuterium atom. For example, one or more hydrogen atoms in a salt or compound of the present disclosure can be replaced or substituted by deuterium atoms. In some embodiments, the salt or compound includes two or more deuterium atoms. In some embodiments, the salt or compound includes 1, 2, 3, 4, 5, 6, 7 or 8 deuterium atoms. In some embodiments, the hydrogen atoms in ditosylate salt or compound I as described herein can be replaced or substituted by 1 to 32 deuterium atoms. In some embodiments, the hydrogen atoms on the cyclopropyl group in Compound I can be replaced or substituted with 1, 2, 3 or 4 deuterium atoms. In some embodiments, all the hydrogen atoms on the phenyl group in Compound I can be replaced or substituted with deuterium atoms. In some embodiments, the hydrogen atoms on the -CH2- linkage between the piperidine and the NH moieties in Compound I can be replaced or substituted with 1 or 2 deuterium atoms. In some embodiments, the hydrogen atoms on the methoxymethyl group in Compound I can be replaced or substituted with 1 to 5 deuterium atoms. In some embodiments, the hydrogen atoms on the cyclobutyl and/or the piperidine ring in Compound I can be replaced or substituted by 1 to 14 deuterium atoms. Synthetic methods for including isotopes into organic compounds are known in the art. All salts and compounds described herein can be found together with other substances such as water and solvents (e.g., hydrates and solvates) or can be isolated. When in the solid state, the salts and compounds described herein may occur in various forms and may, e.g., take the form of solvates, including hydrates. In some embodiments, the salts or crystalline forms of the invention are substantially isolated. By "substantially isolated" is meant that the salt or crystalline form is at least partially or substantially separated from the environment in which it was formed or detected. Partial separation can include, e.g., a composition enriched in the salts or crystalline forms of 38 5 10 15 20 25 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 the invention. Substantial separation can include compositions containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% by weight of the salts or crystalline forms of the invention. Synthetic Preparation In another aspect, the present disclosure provides methods for preparing the di¬ tosylate salt of Compound I, i.e. l-{[4-(methoxymethyl)-4-({[(lR,2S)-2- phenyIcyclopropy1]amino}methyl)piperidin-1-yl]methyl}cyclobutanecarboxylic acid bis(4- methylbenzenesulfonate). The method includes reacting 1-{[4-({(tertbutoxycarbonyl)[(lR,2S)-2-phenylcyclopropyl]amino}methyl)-4-(methoxymethyl)piperidinI -yl|methyl}cyclobutanecarboxylie acid (11) having the formula: with p-toluenesul Tonic acid (TsOH) in a solvent under conditions sufficient to form -{[4- (methoxymethyl)-4-({[(1R,2S)-2-phenyIcyclopropy1]amino}methyl)piperidin-1- yl]methyl}cyclobutanecarboxylic acid bis(4-methylbenzenesulfonate). In some embodiments, at least about 2 molar equivalents of p-toluenesulfonic acid is used in the reaction, with respect to the amount of compound (11). Suitable solvents for carrying out the reaction include, but are not limited to, THF, dioxane, dimethylformamide, 2-methyl-THF, acetone, methyl t-butyl ether, water, 2-butanone and combinations thereof. In one embodiment, the reaction is carried out in THF. In some embodiments, the method can include a further step of recrystallization ofl-{[4-(methoxymethyl)-4-({[(lR,2S)-2- phenylcyclopropyl]ammo}methyl)piperidin-l-yl]methyl}cyclobutanecarboxylic acid bis(4- methylbenzenesulfonate). Suitable solvents for recrystallization include, but are not limited to, THF, 2-methyl-THF, hexane/2-butanone, heptane/2-butanone, dimethylformamide, acetone, acetonitrile and combinations thereof. In one embodiment, the recrystallization is carried out in mixed solvents of heptane and 2-butanone. The reaction is generally carried out at a temperature range of about 50 to 60 °C or 55 to 60 °C. In one embodiment, the reaction is carried at about 55 °C. 39 5 10 15 20 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 The present disclosure further provides a method for preparing compound (11). The method includes reacting compound (10) benzyl l-{[4-({(tert-butoxycarbonyl)[(lR,2S)-2- phenylcyclopropyl]amino}methyl)-4-(methoxymethyl)piperidin-lyl]methyl}cyclobutanecarboxylate having the formula: with a base such as KOH, NaOH, LiOH, or CsOH in a solvent such as ethanol or a mixture of water/ethanol. In some embodiments, the base is employed to hydrolyze the benzyl ester moiety in Compound 10. In one embodiment, the reaction is carried out at 40 °C. In some embodiments, once the hydrolysis reaction is complete, an acid (such as HC1, e.g., aqueous HC1) is added to the reaction mixture to neutralize the mixture. In some embodiments, the present disclosure provides a method for preparing compound (10). The method includes reacting benzyl l-((4-(methoxymethyl)-4-(((lR,2S)-2- phenylcyclopropylamino)methyl)piperidin-1-yl)methyl)cyclobutanecarboxylate (9) (10 L-tartrate) with di-t-butyl dicarbonate in a solvent such as dichloromethane to form l-{[4-({(tert¬ butoxycarbonyl)[(lR,2S)-2-phenylcyclopropyl]amino}methyl)-4-(methoxymethyl)piperidin- 1-yl]methyl}cyclobutanecarboxylic acid. Compound (10) can be purified. For example, the purification includes reacting compound (10) with L-tartaric acid to form compound (10) L-tartrate: 40 5 10 15 20 25 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 optionally in the presence of one or more solvents (e.g., isopropanol, methanol, and nheptane); and reacting compound (10) L-tartrate with NaHCOs to form purified compound (10) optionally in the presence of a solvent (e.g., dichloromethane). L-tartaric acid can form a crystalline salt with compound 10, which is effective in removing impurities in compound 10. In some embodiments, after said purification process, the purity of compound 10 is greater than about 99% as compared to the purity of compound 10 without undergoing said purification process, which can range from about 90% to about 95%. In some embodiments, the present disclosure provides a method for preparing compound (9). The method includes dissolving benzyl l-{[4-formyl-4- (methoxymethyl)piperidin-l-yl]methyl} cyclobutanecarboxylate (7) having the formula: and (lR,2S)-2-phenylcyclopropanamine (8) in a solvent such as dichloromethane to form a mixture; and reacting the mixture with a reducing agent in a solvent under conditions sufficient to form compound (9). Suitable reducing agents include, but are not limited to, NaBH(OAc)3, NaBH4, LiAlH4, diisobutylaluminium hydride, lithium triethylborohydride, sodium bis(2-methoxyethoxy)aluminumhydride, and sodium cyanoborohydride. Suitable solvents include, but are not limited to, dichloromethane, THF, hexane, benzene, ether, methanol, acetic acid, acetonitrile or combinations thereof. In one embodiment, the solvent is dichloromethane or a mixture of dichloromethane and acetic acid. In another aspect, the present disclosure provides synthetic intermediates that are useful for the synthesis of tosylate salts of Compound I. In some embodiments, the present disclosure provides a synthetic intermediate having Formula (II): where R1 is Ci-6alkyl or Ci-ehaloalkyl; R2 is halo, CN, Ci-6 alkyl, Ci-6 alkoxy, Ci-4haloalkyl, or Ci-4 haloalkoxy; R3 is H or a labile group; and the subscript n is 0, 1, 2 or 3. In some embodiments of compounds of formula (II), R1 is CTh In other embodiments of compounds 41 5 10 15 20 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 of formula (II), n is 0. In other embodiments of compounds of formula (II), R3 is H, ptoluenesulfonyl, methanesulfonyl or trifluoromethanesulfonyl. In other embodiments of compounds of formula (II), R3 is H. In one embodiment of compounds of formula (II), R1 is CH3, n is 0 and R3 is H. In some embodiments, the present disclosure provides a synthetic intermediate having Formula (III): O R4 (III) where R4 is C1-6alkyl or C1-6 haloalkyl; R5 is halo, CN, C1-6 alkyl, C1-6 alkoxy, C1-4 haloalkyl, or Ci-4 haloalkoxy; R6 is H or halo; and the subscript m is 0, 1, 2 or 3. In some embodiments of compounds of formula (III), R4 is CH3. In some embodiments of compounds of formula (III), m is 0. In some embodiments of compounds of formula (III), R6 is H, Cl or Br. In some embodiments of compounds of formula (III), R6 is H. In one embodiment of compounds of formula (III), R4 is CH3, R6 is H and m is 0. In some embodiments, the present disclosure provides a synthetic intermediate having Formula (IV): (IV) where R7 is C1-6alkyl or C1-6 haloalkyl; R8 is halo, CN, C1-6 alkyl, C1-6 alkoxy, C1-4 haloalkyl, or C1-4 haloalkoxy; R9 is halo, CN, C1-6 alkyl, C1-6 alkoxy, C1-4 haloalkyl, or C1-4 haloalkoxy; the subscript p is 0, 1, 2 or 3; and the subscript q is 0, 1, 2 or 3. In some embodiments of compounds of formula (IV), R7 is CH3. In some embodiments of compounds of formula (IV), p is 0. In some embodiments of compounds of formula (IV), q is 0. In some embodiments of compounds of formula (IV), R7 is CH3, p is 0 and q is 0. In some embodiments, the present disclosure provides a synthetic intermediate having Formula (V): 42 5 10 15 20 25 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 where R7 is Ci-6alkyl or Ci-6 haloalkyl; R8 is halo, CN, Ci-6 alkyl, Ci-6 alkoxy, Ci-4 haloalkyl, or Ci-4 haloalkoxy; R10 is an amino protecting group; R11 is a carboxyl or hydroxyl protecting group; and the subscript p is 0, 1, 2 or 3. In some embodiments of compounds of formula (V), R7 is CH3. In some embodiments of compounds of formula (V), R10 is t-butoxycarbonyl. In some embodiments of compounds of formula (V), p is 0. In some embodiments of compounds of formula (V), R11 is a benzyl group, wherein the phenyl is optionally substituted with 1-3 R9 substituents. In some embodiments of compounds of formula (V), R11 is a benzyl group. In some embodiments of compounds of formula (V), R7 is GTE, R10 is t-butoxycarbonyl, R11 is benzyl and p is 0. In some embodiments, the present disclosure provides a synthetic intermediate having Formula (VI): where R7 is Ci-6alkyl or Ci-6 haloalkyl; R8 is halo, CN, Ci-6 alkyl, Ci-6 alkoxy, Ci-4 haloalkyl, or Ci-4 haloalkoxy; R10 is an amino protecting group; and the subscript p is 0, 1, 2 or 3. In some embodiments of compounds of formula (VI), R7 is CIE In some embodiments of compounds of formula (VI), R10 is t-butoxycarbonyl. In some embodiments of compounds of formula (VI), p is 0. In some embodiments of compounds of formula (V), R7 is CH3, R10 is t-butoxycarbonyl, and p is 0. The intermediate compounds of formulas (II), (III), (IV), (V) or (VI) can be prepared using the synthetic protocols set forth in Example 1. The processes described herein can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., or 13C), infrared spectroscopy, spectrophotometry (e.g., UV-visible), or mass spectrometry; or by chromatography such as high performance liquid chromatography (HPLC) or thin layer chromatography. The 43 5 10 15 20 25 30 Date Reçue/Date Received 2023-01-27 84193183 compounds obtained by the reactions can be purified by any suitable method known in the art. For example, chromatography (medium pressure) on a suitable adsorbent (e.g., silica gel, alumina and the like), HPLC, or preparative thin layer chromatography; distillation; sublimation, trituration, or recrystallization. The purity of the compounds, in general, are determined by physical methods such as measuring the melting point (in case of a solid), obtaining aNMR spectrum, or performing a HPLC separation. If the melting point decreases, if unwanted signals in the NMR spectrum are decreased, or if extraneous peaks in an HPLC trace are removed, the compound can be said to have been purified. In some embodiments, the compounds are substantially purified. Preparation of compounds can involve the protection and deprotection of various chemical groups. The need for protection and deprotection, and the selection of appropriate protecting groups can be readily determined by one skilled in the art. The chemistry of protecting groups can be found, for example, in Wuts and Greene, Greene’s Protective Groups in Organic Synthesis, 4th Ed., John Wiley & Sons: New York, 2006. The reactions of the processes described herein can be carried out at appropriate temperatures which can be readily determined by the skilled artisan. Reaction temperatures will depend on, for example, the melting and boiling points of the reagents and solvent, if present; the thermodynamics of the reaction (e.g., vigorously exothermic reactions may need to be carried out at reduced temperatures); and the kinetics of the reaction (e.g., a high activation energy barrier may need elevated temperatures). “Elevated temperature” refers to temperatures above room temperature (about 22 °C). The reactions of the processes described herein can be carried out in suitable solvents which can be readily selected by one of skill in the art of organic synthesis. Suitable solvents can be substantially non-reactive with the starting materials (reactants), the intermediates, or products at die temperatures at which the reactions are carried out, i.e., temperatures which can range from the solvent’s freezing temperature to the solvent’s boiling temperature. A given reaction can be carried out in one solvent or a mixture of more than one solvent. Depending on the reaction step, suitable solvents) for that particular reaction step can be selected. Appropriate solvents include water, alkanes (such as pentanes, hexanes, heptanes, cyclohexane, etc., or a mixture thereof), aromatic solvents (such as benzene, toluene, xylene, etc.), alcohols (such as methanol, ethanol, isopropanol, etc.), ethers (such as dialkylethers, 44 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 methyl tert-butyl ether (MTBE), tetrahydrofuran (THF), dioxane, etc ), esters (such as ethyl acetate, butyl acetate, etc.), halogenated hydrocarbon solvents (such as dichloromethane (DCM), chloroform, dichloroethane, tetrachloroethane), dimethylformamide (DMF), dimethylsulfoxide (DMSO), acetone, acetonitrile (ACN), hexamethylphosphoramide (HMPA) and N-methyl pyrrolidone (NMP). Such solvents can be used in either their wet or anhydrous forms. Resolution of racemic mixtures of compounds can be carried out by any of numerous methods known in the art. An example method includes fractional recrystallization using a “chiral resolving acid” which is an optically active, salt-forming organic acid. Suitable resolving agents for fractional recrystallization methods are, for example, optically active acids, such as the D and L forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid or the various optically active camphorsulfonic acids. Resolution of racemic mixtures can also be carried out by elution on a column packed with an optically active resolving agent (e.g., dinitrobenzoylphenylglycine). Suitable elution solvent composition can be determined by one skilled in the art. Methods of Use Tosylate salts of Compound I as described herein, including di-tosylate salts, can inhibit the activity of LSD1 and, thus, are useful in treating diseases and disorders associated with activity of LSD1. The present disclosure provides methods of treating an LSD1- associated or mediated disease or disorder in an individual (e.g., patient) by administering to the individual in need of such treatment a therapeutically effective amount or dose of Compound I tosylate salt, or any of the embodiments thereof, or a pharmaceutical composition thereof. The present disclosure also provides a Compound I di-tosylate salt, or any of the embodiments thereof, or a pharmaceutical composition thereof, for use in treating an LSD1-associated or mediated disease or disorder. Also provided is the use of Compound I p-toluenesulfonic acid salt, or any of the embodiments thereof, or a pharmaceutical composition thereof, in the manufacture of a medicament for treating an LSDl-associated or mediated disease or disorder. An LSDl-associated or mediated disease refers to any disease or condition in which LSD1 plays a role, or where the disease or condition is associated with expression or activity of LSD1. An LSDl-associated disease can include any disease, disorder or condition that is 45 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 directly or indirectly linked to expression or activity of the LSD1, including over-expression and/or abnormal activity levels. Abnormal activity levels can be determined by comparing activity level in normal, healthy tissue or cells with activity level in diseased cells. An LSD1- associated disease can also include any disease, disorder or condition that can be prevented, ameliorated, inhibited or cured by modulating LSD1 activity. In some embodiments, the disease is characterized by the abnormal activity or expression (e g., overexpression) of LSD1. In some embodiments, the disease is characterized by mutant LSD1. An LSD1 associated disease can also refer to any disease, disorder or condition wherein modulating the expression or activity of LSD1 is beneficial. The tosylate salts of the present disclosure can therefore be used to treat or lessen the severity of diseases and conditions where LSD1 is known to play a role. Diseases and conditions treatable using the tosylate salts of the present disclosure include, generally cancers, inflammation, autoimmune diseases, viral induced pathogenesis, beta-globinopathies, and other diseases linked to LSD1 activity. Cancers treatable using tosylate salts according to the present disclosure include, for example, hematological cancers, sarcomas, lung cancers, gastrointestinal cancers, genitourinary tract cancers, liver cancers, bone cancers, nervous system cancers, gynecological cancers, and skin cancers. Exemplary hematological cancers include lymphomas and leukemias such as acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), acute promyelocytic leukemia (APL), chronic lymphocytic leukemia (CLL), chronic myelogenous leukemia (CML), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, Non-Hodgkin lymphoma (including relapsed or refractory NHL and recurrent follicular), Hodgkin lymphoma, myeloproliferative diseases (e.g., primary myelofibrosis (PMF), polycythemia vera (PV), essential thrombocytosis (ET)), myelodysplasia syndrome (MDS), T-cell acute lymphoblastic lymphoma (T-ALL) and multiple myeloma. Exemplary sarcomas include chondrosarcoma, Ewing’s sarcoma, osteosarcoma, rhabdomyosarcoma, angiosarcoma, fibrosarcoma, liposarcoma, myxoma, rhabdomyoma, rhabdosarcoma, fibroma, lipoma, harmatoma, and teratoma. Exemplary lung cancers include non-small cell lung cancer (NSCLC), small cell lung cancer, bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated 46 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, chondromatous hamartoma, and mesothelioma. Exemplaiy gastrointestinal cancers include cancers of the esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small bowel (adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large bowel (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma), and colorectal cancer. Exemplary genitourinary tract cancers include cancers of the kidney (adenocarcinoma, Wilm's tumor [nephroblastoma]), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), and testis (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma). Exemplary liver cancers include hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, and hemangioma. Exemplary bone cancers include, for example, osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticulum cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochronfroma (osteocartilaginous exostoses), benign chondroma, chondroblastoma, chondromyxofibroma, osteoid osteoma, and giant cell tumors Exemplary nervous system cancers include cancers of the skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), meninges (meningioma, meningiosarcoma, gliomatosis), brain (astrocytoma, meduoblastoma, glioma, ependymoma, germinoma (pinealoma), glioblastoma, glioblastoma multiform, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), and spinal cord (neurofibroma, meningioma, glioma, sarcoma), as well as neuroblastoma and Lhermitte-Duclos disease. Exemplary gynecological cancers include cancers of the uterus (endometrial carcinoma), cervix (cervical carcinoma, pre -tumor cervical dysplasia), ovaries (ovarian carcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified 47 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 carcinoma), granulosa-thecal cell tumors, Sertoli-Leydig cell tumors, dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), and fallopian tubes (carcinoma). Exemplary skin cancers include melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, moles dysplastic nevi, lipoma, angioma, dermatofibroma, and keloids. The tosylate salts of the present disclosure can further be used to treat cancer types where LSD1 may be overexpressed including, for example, breast, prostate, head and neck, laryngeal, oral, and thyroid cancers (e g., papillary thyroid carcinoma). The tosylate salts of the present disclosure can further be used to treat genetic disorders such as Cowden syndrome and Bannayan-Zonana syndrome. The tosylate salts of the present disclosure can further be used to treat viral diseases such as herpes simplex virus (HSV), varicella zoster virus (VZV), human cytomegalovirus, hepatitis B virus (HBV), and adenovirus. The tosylate salts of the present disclosure can further be used to treat betaglobinopathies including, for example, beta-thalassemia and sickle cell anemia. The tosylate salts of the present disclosure can be used to treat triple-negative breast cancer (TNBC), myelodysplastic syndromes, testicular cancer, bile duct cancer, esophageal cancer, and urothelial carcinoma. In some embodiments, the salts of the present disclosure may be useful in preventing or reducing the risk of developing the disease; e.g., preventing or reducing the risk of developing a disease, condition or disorder in an individual who may be predisposed to the disease, condition or disorder but does not yet experience or display the pathology or symptomatology of the disease. Combination Therapies Cancer cell growth and survival can be impacted by multiple signaling pathways. Thus, it is useful to combine different kinase inhibitors, exhibiting different preferences in the kinases which they modulate the activities of, to treat such conditions. Targeting more than one signaling pathway (or more than one biological molecule involved in a given signaling 48 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 pathway) may reduce the likelihood of drug-resistance arising in a cell population, and/or reduce the toxicity of treatment. The salts of the LSD1 inhibitor as described herein can be used in combination with one or more other kinase inhibitors for the treatment of diseases, such as cancer, that are impacted by multiple signaling pathways. For example, a combination can include one or more inhibitors of the following kinases for the treatment of cancer: Aktl, Akt2, Akt3, TGFPR, Pim, PKA, PKG, PKC, CaM-kinase, phosphorylase kinase, MEKK, ERK, MAPK, mTOR, EGFR, HER2, HER3, HER4, INS-R, IGF-1R, IR-R, PDGFaR, PDGFpR, CSFIR, KIT, FLK-II, KDR/FLK-1, FLK-4, flt-1, FGFR1, FGFR2, FGFR3, FGFR4, c-Met, Ron, Sea, TRKA, TRKB, TRKC, FLT3, VEGFR/Flt2, Flt4, EphAl, EphA2, EphA3, EphB2, EphB4, Tie2, Src, Fyn, Lek, Fgr, Btk, Fak, SYK, FRK, JAK, ABL, ALK and B-Raf. Additionally, the salts of the LSD1 inhibitor as described herein can be combined with inhibitors of kinases associated with the PIK3/Akt/mTOR signaling pathway, such as PI3K, Akt (including Aktl, Akt2 and Akt3) and mTOR kinases. In some embodiments, the salts of the LSD1 inhibitor as described herein can be used in combination with a therapeutic agent that targets an epigenetic regulator. Examples of epigenetic regulators include bromodomain inhibitors, the histone lysine methyltransferases, histone arginine methyl transferases, histone demethylases, histone deacetylases, histone acetylases, and DNA methyltransferases. Histone deacetylase inhibitors include, e.g., vorinostat. For treating cancer and other proliferative diseases, the salts of the LSD1 inhibitor as described herein can be used in combination with chemotherapeutic agents, agonists or antagonists of nuclear receptors, or other anti-proliferative agents. The compounds of the invention can also be used in combination with a medical therapy such as surgery or radiotherapy, e.g., gamma-radiation, neutron beam radiotherapy, electron beam radiotherapy, proton therapy, brachytherapy, and systemic radioactive isotopes. Examples of suitable chemotherapeutic agents include any of: abarelix, aldesleukin, alemtuzumab, alitretinoin, allopurinol, altretamine, anastrozole, arsenic trioxide, asparaginase, azacitidine, bendamustine, bevacizumab, bexarotene, bleomycin, bortezombi, bortezomib, busulfan intravenous, busulfan oral, calusterone, capecitabine, carboplatin, carmustine, cetuximab, chlorambucil, cisplatin, cladribine, clofarabine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, dalteparin sodium, dasatinib, daunorubicin, decitabine, denileukin, denileukin 49 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 diftitox, dexrazoxane, docetaxel, doxorubicin, dromostanolone propionate, eculizumab, epirubicin, erlotinib, estramustine, etoposide phosphate, etoposide, exemestane, fentanyl citrate, filgrastim, floxuridine, fludarabine, fluorouracil, fulvestrant, gefitinib, gemcitabine, gemtuzumab ozogamicin, goserelin acetate, histrelin acetate, ibritumomab tiuxetan, idarubicin, ifosfamide, imatinib mesylate, interferon alfa 2a, irinotecan, lapatinib ditosylate, lenalidomide, letrozole, leucovorin, leuprolide acetate, levamisole, lomustine, meclorethamine, megestrol acetate, melphalan, mercaptopurine, methotrexate, methoxsalen, mitomycin C, mitotane, mitoxantrone, nandrolone phenpropionate, nelarabine, nofetumomab, oxaliplatin, paclitaxel, pamidronate, panobinostat, panitumumab, pegaspargase, pegfilgrastim, pemetrexed disodium, pentostatin, pipobroman, plicamycin, procarbazine, quinacrine, rasburicase, rituximab, ruxolitinib, sorafenib, streptozocin, sunitinib, sunitinib maleate, tamoxifen, temozolomide, teniposide, testolactone, thalidomide, thioguanine, thiotepa, topotecan, toremifene, tositumomab, trastuzumab, tretinoin, uracil mustard, valrubicin, vinblastine, vincristine, vinorelbine, vorinostat, and zoledronate. In some embodiments, biological anticancer drugs, such as antibodies and cytokines, can be combined with the salts of the LSD1 inhibitor as described herein. In addition, drugs modulating microenvironment or immune responses can be combined with the compounds of the invention. Examples of such drugs include anti-Her2 antibodies, anti-CD20 antibodies, anti-CTLAl, anti-PD-1, anti-PDLl, and other immunotherapeutic drugs. For treating cancer and other proliferative diseases, the salts of the LSD1 inhibitor as described herein can be used in combination with targeted therapies, including FGFR inhibitors (FGFR1, FGFR2, FGFR3 or FGFR4), JAK kinase inhibitors (Ruxolitinib, additional JAK1/2 and JAKI-selective, baricitinib or INCB39110), Pim kinase inhibitors, PI3 kinase inhibitors including PI3K-delta selective and broad spectrum PI3K inhibitors, PI3Kgamma inhibitors such as PI3K-gamma selective inhibitors, MEK inhibitors, CSF1R inhibitors, TAM receptor tyrosine kinases inhibitors (Tyro-3, Axl, and Mer), angiogenesis inhibitors, interleukin receptor inhibitors, Cyclin Dependent kinase inhibitors, BRAF inhibitors, mTOR inhibitors, proteasome inhibitors (Bortezomib, Carfilzomib), HDACinhibitors (panobinostat, vorinostat), DNA methyl transferase inhibitors, dexamethasone, bromo and extra terminal family members inhibitors (for example, bromodomain inhibitors or BET inhibitors), and indoleamine 2,3-dioxygenase inhibitors (epacadostat and NLG919). 50 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 In some embodiments, the salts of the LSD1 inhibitor as described herein can be used in combination with immune checkpoint inhibitors. Exemplary immune checkpoint inhibitors include inhibitors against immune checkpoint molecules such as CD27, CD28, CD40, CD122, CD96, CD73, CD47, OX40, GITR, CSF1R, JAK, PI3K delta, PI3K gamma, TAM, arginase, CD137 (also known as 4-1BB), ICOS, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, LAG3, TIM3, VISTA, PD-1, PD-L1 and PD-L2. In some embodiments, the immune checkpoint molecule is a stimulatory checkpoint molecule selected from CD27, CD28, CD40, ICOS, 0X40, GITR and CD137. In some embodiments, the immune checkpoint molecule is an inhibitory checkpoint molecule selected from A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, PD-1, TIM3, and VISTA. In some embodiments, the compounds provided herein can be used in combination with one or more agents selected from KIR inhibitors, TIGIT inhibitors, LAIR1 inhibitors, CD160 inhibitors, 2B4 inhibitors and TGFR beta inhibitors. In some embodiments, the inhibitor of an immune checkpoint molecule is anti-PDl antibody, anti-PD-Ll antibody, or anti-CTLA-4 antibody. In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of PD-1, e.g., an anti-PD-1 monoclonal antibody. In some embodiments, the antiPD-1 monoclonal antibody is nivolumab, pembrolizumab (also known as MK-3475), pidilizumab, SHR-1210, PDR001, ipilumimab or AMP-224. In some embodiments, the antiPD-1 monoclonal antibody is nivolumab or pembrolizumab. In some embodiments, the antiPDl antibody is pembrolizumab. In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of PD-L1, e.g., an anti-PD-Ll monoclonal antibody. In some embodiments, the anti-PD-Ll monoclonal antibody is BMS-935559, MEDI4736, MPDL3280A (also known as RG7446), or MSB0010718C. In some embodiments, the anti-PD-Ll monoclonal antibody is MPDL3280A or MEDI4736. In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of CTLA-4, e.g., an anti-CTLA-4 antibody. In some embodiments, the anti-CTLA- 4 antibody is ipilimumab. In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of LAG3, e.g., an anti-LAG3 antibody. In some embodiments, the anti-LAG3 antibody is BMS-986016 or LAG525. 51 5 10 15 20 25 30 Date Reçue/Date Received 2023-01-27 84193183 In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of GITR, e.g., an anti-GITR antibody. In some embodiments, the anti-GITR antibody is TRX518 or MK-4166. In some embodiments, the inhibitor of an immune checkpoint molecule is an inhibitor of OX40, e.g., an anti-OX40 antibody or OX40L fusion protein. In some embodiments, the anti-0X40 antibody is MEDI0562. In some embodiments, the OX40L fusion protein is MEDI6383. In some embodiments, the salts of the LSD1 inhibitor as described herein can be used in combination with one or more agents for the treatment of diseases such as cancer. In some embodiments, the agent is an alkylating agent, a proteasome inhibitor, a corticosteroid, or an immunomodulatoiy agent. Examples of an alkylating agent include cyclophosphamide (CY), melphalan (MEL), and bendamustine. In some embodiments, the proteasome inhibitor is carfilzomib. In some embodiments, the corticosteroid is dexamethasone (DEX). In some embodiments, the immunomodulatory agent is lenalidomide (LEN) or pomalidomide (POM). For treating autoimmune or inflammatoiy conditions, the salts of the LSD1 inhibitor as described herein can be administered in combination with a corticosteroid such as triamcinolone, dexamethasone, fluocinolone, cortisone, prednisolone, or flumetholone. For treating autoimmune or inflammatory conditions, the salts of the LSD1 inhibitor as described herein can be administered in combination with an immune suppressant such as fluocinolone acetonide (Retisert®), rimexolone (AL-2178, Vexol™, Alcon), or cyclosporine (Restasis®). For treating autoimmune or inflammatoiy conditions, the salts of the LSD1 inhibitor as described herein can be administered in combination with one or more additional agents selected from Dehydrex™ (Hoiles Labs), Civamide (Opko), sodium hyaluronate (Vismed™, Lantibio/TRB Chemedia), cyclosporine (ST-603, Sinon Therapeutics), ARG101(T) (testosterone, Argentis), AGR1012(P) (Argentis). ecabet sodium (Senju-Ista), gefamate (Santen), 15-(s)-hydroxyeicosatetraenoic acid (15(S)-HETE), cevilemine, doxycycline (ALTY-0501, Alacrity), minocycline, iDestrin™ (NP50301, Nascent Pharmaceuticals), cyclosporine A (Nova22007, Novagali), oxytetracycline (Duramycin™, MOLLI901, Lantibio), CF101 (2S, 3S, 4R, 5R)-3, 4-dihydroxy-5-[6-[(3-iodophenyl)methylamino]purin-9-yl]-Nmethyl-oxolane-2-carbamyl, Can-Fite Biopharma), voclosporin (LX212 or LX214, Lux Biosciences), ARG103 (Agentis), RX-10045 (synthetic resolvin analog, Resolvyx), DYN15 52 5 10 15 20 25 30 84193183 (Dyanmis Therapeutics), rivoglitazone (DE011, Daiichi Sanko), TB4 (RegeneRx), OPH-01 (Ophtalmis Monaco), PCS101 (Pericor Science), REV1-31 (Evolutec), Lacritin (Senju), rebamipide (Otsuka-Novartis), OT-551 (Othera), PAI-2 (University of Pennsylvania and Temple University), pilocarpine, tacrolimus, pimecrolimus (AMS981, Novartis), loteprednol etabonate, rituximab, diquafosol tetrasodium (INS365, Inspire), KLS-0611 (Kissei Pharmaceuticals), dehydroepiandrosterone, anakinra, efalizumab, mycophenolate sodium, etanercept (Embrel®), hydroxychloroquine, NGX267 (TorreyPines Therapeutics), or thalidomide. For treating beta-thalassemia or sickle cell disease (sickle cell anemia), the salts of the LSD1 inhibitor as described herein can be administered alone or in combination with one or more additional agents described herein such as Hydrea® (hydroxyurea). In some embodiments, the salts of the LSD1 inhibitor as described herein can be administered in combination with one or more agents selected from an antibiotic, antiviral, antifungal, anesthetic, anti-inflammatory agents including steroidal and non-steroidal anti¬ inflammatories, and anti-allergic agents. Examples of suitable medicaments include aminoglycosides such as amikacin, gentamycin, tobramycin, streptomycin, netilmycin, and kanamycin; fluoroquinolones such as ciprofloxacin, norfloxacin, ofloxacin, trovafloxacin, lomefloxacin, levofloxacin, and enoxacin; naphthyridine; sulfonamides; polymyxin; chloramphenicol; neomycin; paramomycin; colistimethate; bacitracin; vancomycin; tetracyclines; rifampin and its derivatives ("rifampins"); cycloserine; beta-lactams; cephalosporins; amphotericins; fluconazole; flucytosine; natamycin; miconazole; ketoconazole; corticosteroids; diclofenac; flurbiprofen; ketorolac; suprofen; cromolyn; lodoxamide; levocabastin; naphazoline; antazoline; pheniramine; or azalide antibiotic. Other examples of agents, which can be combined with the salts of the LSD1 inhibitor as described herein include: a treatment for Alzheimer's Disease such as donepezil and rivastigmine; a treatment for Parkinson's Disease such as L-DOPA/carbidopa, entacapone, ropinirole, pramipexole, bromocriptine, pergolide, trihexyphenidyl, and amantadine; an agent for treating multiple sclerosis (MS) such as beta interferon (e.g., Avonex® and Rebif®), glatiramer acetate, and mitoxantrone; a treatment for asthma such as albuterol and montelukast; an agent for treating schizophrenia such as Zyprexa™, Risperdal™, Seroquel™, and haloperidol; an anti-inflammatoiy agent such as a corticosteroid, such as dexamethasone or prednisone, a TNF blocker, IL-1 RA, azathioprine, cyclophosphamide, and sulfasalazine; an 53 Date Reçue/Date Received 2023-01-27 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 immunomodulatory agent, including immunosuppressive agents, such as cyclosporin, tacrolimus, rapamycin, mycophenolate mofetil, an interferon, a corticosteroid, cyclophosphamide, azathioprine, and sulfasalazine; a neurotrophic factor such as an acetylcholinesterase inhibitor, an MAO inhibitor, an interferon, an anti-convulsant, an ion channel blocker, riluzole, or an anti-Parkinson's agent; an agent for treating cardiovascular disease such as a beta-blocker, an ACE inhibitor, a diuretic, a nitrate, a calcium channel blocker, or a statin; an agent for treating liver disease such as a corticosteroid, cholestyramine, an interferon, and an anti-viral agent; an agent for treating blood disorders such as a corticosteroid, an anti-leukemic agent, or a growth factor; or an agent for treating immunodeficiency disorders such as gamma globulin. When more than one pharmaceutical agent is administered to a patient, they can be administered simultaneously, sequentially, or in combination (e.g., for more than two agents). Formulation, Dosage Forms and Administration The salts of the present disclosure can be administered in the form of a pharmaceutical composition. Thus the present disclosure provides a composition comprising the salts of the invention, or any of the embodiments thereof, and at least one pharmaceutically acceptable carrier. These compositions can be prepared in a manner well known in the pharmaceutical art, and can be administered by a variety of routes, depending upon whether local or systemic treatment is indicated and upon the area to be treated. Administration may be topical (including transdermal, epidermal, ophthalmic and to mucous membranes including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal or intranasal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal intramuscular or injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Parenteral administration can be in the form of a single bolus dose, or may be, e.g., by a continuous perfusion pump. Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. This disclosure also includes pharmaceutical compositions which contain, as the active ingredient, a salt of the invention, in combination with one or more pharmaceutically acceptable carriers (excipients). In some embodiments, the composition is suitable for topical 54 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 administration. In making the compositions of the invention, the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, e.g., a capsule, sachet, paper, or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, e.g., up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders. In preparing a formulation, the active compound can be milled to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it can be milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, e.g., about 40 mesh. The salts of the invention may be milled using known milling procedures such as wet milling to obtain a particle size appropriate for tablet formation and for other formulation types. Finely divided (nanoparticulate) preparations of the compounds of the invention can be prepared by processes known in the art see, e.g., WO 2002/000196. Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; and sweetening agents and flavoring agents. The compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art. In some embodiments, the pharmaceutical composition comprises silicified microcrystalline cellulose (SMCC) and at least one compound described herein, or a pharmaceutically acceptable salt thereof. In some embodiments, the silicified microcrystalline cellulose comprises about 98% microcrystalline cellulose and about 2% silicon dioxide w/w. 55 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 In some embodiments, the composition is a sustained release composition comprising at least a salt described herein, and at least one pharmaceutically acceptable carrier. In some embodiments, the composition comprises a salt described herein, and at least one component selected from microcrystalline cellulose, lactose monohydrate, hydroxypropyl methylcellulose and polyethylene oxide. In some embodiments, the composition comprises at least one compound described herein, or a pharmaceutically acceptable salt thereof, and microcrystalline cellulose, lactose monohydrate and hydroxypropyl methylcellulose. In some embodiments, the composition comprises at a salt described herein and microcrystalline cellulose, lactose monohydrate and polyethylene oxide. In some embodiments, the composition further comprises magnesium stearate or silicon dioxide. In some embodiments, the microcrystalline cellulose is Avicel PH102™. In some embodiments, the lactose monohydrate is Fast-flo 316™. In some embodiments, the hydroxypropyl methylcellulose is hydroxypropyl methylcellulose 2208 K4M (e.g., Methocel K4 M Premier™) and/or hydroxypropyl methylcellulose 2208 K100LV (e.g., Methocel K00LV™). In some embodiments, the polyethylene oxide is polyethylene oxide WSR 1105 (e.g., Polyox WSR 1105™). In some embodiments, a wet granulation process is used to produce the composition. In some embodiments, a dry granulation process is used to produce the composition. The compositions can be formulated in a unit dosage form, each dosage containing from about 5 to about 1,000 mg (1 g), more usually about 100 mg to about 500 mg, of the active ingredient. In some embodiments, each dosage contains about 10 mg of the active ingredient. In some embodiments, each dosage contains about 50 mg of the active ingredient. In some embodiments, each dosage contains about 25 mg of the active ingredient. The term "unit dosage forms" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient. Solid oral dosage forms include, for example, tablets, capsules, and pills. The components used to formulate the pharmaceutical compositions are of high purity and are substantially free of potentially harmful contaminants (e.g., at least National Food grade, generally at least analytical grade, and more typically at least pharmaceutical grade). Particularly for human consumption, the composition is preferably manufactured or 56 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 formulated under Good Manufacturing Practice standards as defined in the applicable regulations of the U.S. Food and Drug Administration. For example, suitable formulations may be sterile and/or substantially isotonic and/or in full compliance with all Good Manufacturing Practice regulations of the U.S. Food and Drug Administration. The active compound may be effective over a wide dosage range and is generally administered in a therapeutically effective amount. It will be understood, however, that the amount of the compound actually administered will usually be determined by a physician, according to the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight and response of the individual patient, the severity of the patient's symptoms and the like. The therapeutic dosage of a compound of the present invention can vary according to, e.g., the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The proportion or concentration of a compound of the invention in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration. For example, the compounds of the invention can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration. Some typical dose ranges are from about 1 pg/kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day. The dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems. For preparing solid compositions such as for tablets, capsules, pills, or other oral dosage forms, the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention. When referring to these preformulation compositions as homogeneous, the active ingredient is typically dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation is then subdivided into unit 57 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 dosage forms of the type described above containing from, e.g., about 0.1 to about 1000 mg of the active ingredient of the present invention. The tablets or pills of the present invention can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate. The liquid forms in which the compounds and compositions of the present invention can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face mask, tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions can be administered orally or nasally from devices which deliver the formulation in an appropriate manner. Topical formulations can contain one or more conventional carriers. In some embodiments, ointments can contain water and one or more hydrophobic carriers selected from, e.g., liquid paraffin, polyoxyethylene alkyl ether, propylene glycol, white Vaseline® (petroleum jelly) and the like. Carrier compositions of creams can be based on water in combination with glycerol and one or more other components, e.g., glycerinemonostearate, PEG-glycerinemonostearate and cetylstearyl alcohol. Gels can be formulated using isopropyl alcohol and water, suitably in combination with other components such as, e.g., glycerol, 58 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 hydroxyethyl cellulose and the like. In some embodiments, topical formulations contain at least about 0.1, at least about 0.25, at least about 0.5, at least about 1, at least about 2, or at least about 5 wt % of the compound of the invention. The topical formulations can be suitably packaged in tubes of, e.g., 100 g which are optionally associated with instructions for the treatment of the select indication, e.g., psoriasis or other skin condition. The amount of compound or composition administered to a patient will vary depending upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, the state of the patient, the manner of administration and the like. In therapeutic applications, compositions can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. Effective doses will depend on the disease condition being treated as well as by the judgment of the attending clinician depending upon factors such as the severity of the disease, the age, weight and general condition of the patient and the like. The compositions administered to a patient can be in the form of pharmaceutical compositions described above. These compositions can be sterilized by conventional sterilization techniques, or may be sterile filtered. Aqueous solutions can be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the compound preparations typically will be between 3 and 11, more preferably from 5 to 9 and most preferably from 7 to 8. It will be understood that use of certain of the foregoing excipients, carriers or stabilizers will result in the formation of pharmaceutical salts. The therapeutic dosage of a compound of the present invention can vary according to, e.g., the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The proportion or concentration of a compound of the invention in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (eg., hydrophobicity), and the route of administration. For example, the compounds of the invention can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w/v of the compound for parenteral administration. Some typical dose ranges are from about 1 pg/kg to about 1 g/kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg/kg to about 100 mg/kg of body weight per day. The dosage is likely to depend on such variables as the type and extent of 59 5 10 15 20 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems. It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, can also be provided in combination in a single embodiment (while the embodiments are intended to be combined as if written in multiply dependent form). Conversely, various features of the invention which are, for brevity, described in the context of a single embodiment, can also be provided separately or in any suitable subcombination. The invention will be described in greater detail by way of specific examples. The following examples are offered for illustrative purposes, and are not intended to limit the invention in any manner. Those of skill in the art will readily recognize a variety of noncritical parameters which can be changed or modified to yield essentially the same results. EXAMPLES Example 1. Synthesis of l-{[4-(methoxymethyl)-4-({[(lR,2S)-2-phenylcyclopropyl]amino}methyl)piperidinl-yl]methyl}cyclobutanecarboxylic acid bis(4-methylbenzenesulfonate) (12) (Compound (I) di¬ tosylate salt) Scheme 1. 60 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 -fir" — ff-o 5a 5b 5 oxalyl chloride DMSO 80% I Na(OAc)3BH, HOAc DCM, 25oC, 12h 61 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 recrystalization Compound I di-tosylate salt Stepl. Synthesis of 1-tert-butyl 4-(methoxymethyl)piperidme-l,4-dicarboxylate (2): LDA, THF -40oC, 2h 5 To asolution ofN,N-diisopropylamine (165.0 mL, 1180 mmol) in THF was added 2.5 M n-butyllithium in hexane (0.46 L, 1150 mmol) at -78 °C. The reaction mixture was stirred at -78 °C for 15 minutes, and warmed to 0 °C for 20 minutes. The above prepared LDA solution was added to a flask containing 1-t-butyl 4-methyl piperidine-1,4-dicarboxylate (200.0g, 822.03 mmol) in THF (2.4 L) at -78 °C. The reaction 10 mixture was stirred at -78°C for 10 minutes, then warmed to -40 °C over 1 hour. The reaction mixture was re-cooled to -78 °C, then chloromethyl methyl ether (93.6 mL, 1230 mmol) was added dropwise. The mixture was stirred for 2.5 hours allowing the reaction to come to room temperature. The reaction mixture was quenched with saturated aqueous NaHCOs, and extracted with ethyl acetate (2x1.5 L). The combined organics were washed with water and 15 brine, dried over MgSO4, filtered and concentrated to give an oil product (2). The residue was used in the next step without further purification (quantitative yield). 1H NMR (400 MHz, CDCh) 5 3.85 (d, J= 13.9 Hz, 2H), 3.74 (s, 3H), 3.39 (s, 2H), 3.31 (s, 3H), 3.02-2.90 (m, 2H), 2.13-2.03 (m, 2H), 1.40-1.46 (m, 11H). 62 5 10 15 20 25 84193183 Step 2. Synthesis of tert-butyl 4-(hydroxymethyl)-4-(methoxymethyl)piperidine-l-carboxylate (3) To a dried 22 L 5-neck round bottom flask equipped with stir shaft for mechanical stirring, thermocouple, N2 inlet, addition tube and yellow cap for pressure release was charged 3225 mL dry THF. The solution was cooled to -15 °C using dry ice/IPA bath and charged 1.0 M lithium tetrahydroaluminate in THF (1180 mL, 1180 mmol) to the reactor via cannula directly from vender bottles (the additional LAH was used for EtOAc that is present in the substrate by NMR). The mixture was allowed to warm to -5 °C. A solution of 1-tertbutyl 4-(methoxymethyl)piperidine-l,4-dicarboxylate (429.50 g, 1494.7 mmol) in THF (4000 mL) was prepared and transferred to a 12 L round bottom flask. The ester was slowly added to the LAH solution using positive N2 pressure to deliver solution via addition tube (like a plastic cannula). The internal temperature was kept below 8 °C during addition by adjusting the rate of addition. The reaction mixture was stirred at 0 °C for 1 hour. The reaction mixture was quenched using aq. 1.ON NaOH (260 mL). The initial 21 mL was added slowly under N2. Vigorous H2 evolution and a temperature increase were observed during this part of the quench. Temperature was not allowed to increase above 8 °C. Solids began to form and aqueous addition could be performed more rapidly without noticeable gas evolution and temperature increase. Total quenching time was 20 minutes. The mixture was allowed to stir for 15 minutes to break up solids. Celite™ (500 g) was added and stirred for 45 minutes. The mixture was filtered. The filter cake was washed with ethyl acetate (EtOAc) (2000 mL). The filtrate was added to separation funnel and partitioned between EtOAc (6000 mL) and water (1000 mL). Layers were slow to separate. Some emulsion was observed. The material was purified by Biotage (0-30% EtOAc in hexane) to get pure product (3) (369.5 g, 95.3%). XH NMR (400 MHz, CDCh) 8 3.62 (s, 2H), 3.45 (d, J = 2.3 Hz, 1H), 3.41- 3.32 (m, 7H), 2.33 (s, 2H), 1.55- 1.42 (m, 13H). Step 3. Synthesis of[4-(methoxymethyl)piperidin-yl]methanol hydrochloride (4): 63 Date Reçue/Date Received 2023-01-27 5 10 15 20 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 To a solution of Ze/7-butyl 4-(hydroxymethyl)-4-(methoxymethyl)piperidine-lcarboxylate (113.70 g, 438.42 mmol) in DCM (0.667 L) was added 4.0 M HC1 in dioxane (0.767 mL, 3070 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 1 hour. Filtration of the reaction mixture provided pure product (4) (77.0 g, 89.8%). LC-MS calculated for C24H18CINO2 [M+H]+ m/z: 196.1; found 196.1. 'H NMR (400 MHz, DMSO) 5 9.02 (s, 1H), 3.31- 3.18 (m, 7H), 2.98 (d, J= 6.0 Hz, 4H), 1.61- 1.53 (m, 4H). Step 4. Synthesis of dibenzyl cyclobutane-l,l-dicarboxylate(5b): Benzyl bromide, Et3N OoC to rt, overnight 5a 5b To a solution of 1,1-cyclobutanedicarboxylic acid (50.00 g, 346.9 mmol) in DMF (180 rnL) was added trimethylamine (102 mL, 728 mmol) at 0 °C (keeping temperature below 15 °C during the addition). The reaction mixture was stirred at 0 °C for 15 minutes, then benzyl bromide (144 mL, 1210 mmol) was added (keeping temperature below 30 °C). After 10 minutes, the ice bath was removed. The reaction mixture was stirred at room temperature overnight. To the reaction mixture was added water (300 mL). The mixture was partitioned between DCM (300 mL) and aqueous solution. The organics were washed with 1.0 N HC1 solution (200 mL), 10% NaHCOs solution (200 mL) and brine (200 mL), then dried over MgSO4 and concentrated to give crude material (5b) (111.10 g), which was used for next step. 'H NMR (400 MHz, CDCh) 5 7.37- 7.24 (m, 10H), 5.17 (s, 4H), 2.64- 2.55 (t, J= 8.0 Hz, 4H), 2.02 (p, J= 8.0 Hz, 2H). Step 5. Synthesis of benzyl 1-formylcyclobutanecarboxylate (5): 64 5 10 15 20 25 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 To a solution of dibenzyl cyclobutane-1,1-dicarboxylate (30.00 g, 92.49 mmol) in DCM (200.00 mL) at -75 °C was added 1.0 M diisobutylaluminum hydride in DCM (185 mL) dropwise. The temperature was controlled between -70 °C and -60°C. The reaction mixture was stirred at -75 °C for 1 hour. The reaction was quenched with slow addition of 1.0 M hydrogen chloride in water (200.0 mL). The resulting mixture was warmed to room temperature and stirred for another 30 minutes. The mixture was partitioned between DCM and aqueous solution. The organic layer was washed with water and brine, dried over MgSOr and concentrated to give crude product. Biotage (0-10% EtOAc in hexane) gave pure product (5) 11.6g. 'HNMR (400 MHz, CDCk) 5 9.82 (s, 1H), 7.37 (p, J= 4.3 Hz, 5H), 5.25 (s, 2H), 2.51 (t, J= 8.0 Hz, 4H), 2.11- 1.89 (p, J= 8.0 Hz, 2H). Step 6. Synthesis of benzyl l-((4-(hydroxymethyl)-4-(methoxymethyl)piperidin-lyl)methyl)cyclobutane-l-carboxylate (6): To a solution of [4-(methoxymethyl)piperidin-4-yl]methanol hydrochloride (10.8 g, 55.4mmol) and benzyl 1-formylcyclobutanecarboxylate (14.40 g, 52.78 mmol) in DCM (300 mL) was added trimethylamine (18.4 mL, 132 mmol) at room temperature. The reaction mixture was stirred at room temperature for 1 hour. Sodium triacetoxyborohydride (22.4 g, 106 mmol) was added with a water bath portionwise. The reaction mixture was stirred at room temperature overnight. 65 5 10 15 20 25 84193183 To the reaction mixture was added saturated NaHCOs solution (200 mL). The mixture was partitioned between DCM and NaHCOs solution. The organics were dried and concentrated to provide oil crude product. Biotage™ (EtOAc/hexane: 0-45%) gave pure product (6) (16.6 g, 87%). LC-MS calculated for C21H31NO4 [M+H]+ m/z: 362.2; found 362.2. 'l l NMR (400 MHz, CD3CN) ô 7.47- 7.30 (m, 5H), 5.16 (s, 2H), 3.38 (s, 2H), 3.30 (s, 3H), 3.24 (s. 2H), 2.71 (s. 2H). 2.43 (ddd, J= 12.1, 9.4, 7.2 Hz, 2H), 2.36- 2.28 (m, 4H), 2.09-1.82 (m,4H),1.39-1.31 (m, 4H). 66 Step 7. Synthesis of Benzyl l-{[4-formyl-4-(methoxymethyl)piperidin-l-yl]methyl} cyclobutanecarboxylate (7): To a solution of oxalyl chloride (226 mL, 339 g, 2.67 moles) in dichloromethane (1.1 L) was added a solution of dimethyl sulfoxide (378 mL, 416 g, 5.32 moles) in dichloromethane (500 mL) over one hour, while maintaining the internal temperature at below -55 °C. After stirring at -50 °C for 30 minutes, a solution of benzyl l-((4- (hydroxymethyl)-4-(methoxymethyl)piperidin-l-yl)methyl)cyclobutane-l-carboxylate(475 g, 1.315 mol) in dichloromethane (1.1 L) was added over 45 minutes, maintaining tie internal temperature below -50 °C. After stirring at -50 °C for 30 minutes, triethylamine (1480 mL, 10.62 moles) was added. The reaction temperature rose to 15 °C during the addition. After stirring for 20 minutes, ice cold water (5 L) was added and the layers were separated. The organic layer was washed with water (2 L) and 10% sodium bicarbonate (6.2 L). Each aqueous layer was re-extracted with dichloromethane (3.5 L). The combined organic layers were concentrated under reduced pressure. The crude product was purified over silica gel (5 kg), eluting with a gradient 0 to 100% ethyl acetate in heptane to give compound (7) (402 g, 85% yield, 98% purity) as colorless oil. LC-MS calculated for C21H29NO4 [M+H]' m/z: 361.2; found 361.2. ‘HNMR (400 MHz, CDsCN) S 9.47 (s, 1H), 7.47- 7.33 (m, 5H), 5.16 (s, 2H), 3.38 (s, 2H), 3.26 (s, 3H), 2.67 (s, 2H), 2.54- 2.38 (m, 4H), 2.16-1.93 (m, 4H), 1.91- 1.78 (m, 4H), 1.38 (ddd, J= 13.9, 10.3, 4.0 Hz, 2H). Date Reçue/Date Received 2023-01-27 5 10 15 20 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 Step 8. Synthesis of benzyl l-((4-(methoxymethyl)-4-(((lR,2S)-2- phenylcyclopropylamino)methyl)piperidin-l-yl)methyl)cyclobutanecarboxylate (9) and Benzyl l-{[4-({(tert-butoxycarbonyl)[(lR,2S)-2-phenylcyclopropyl]amino}methyl)-4- (methoxymethyl)piperidin-l-yl]methyl}cyclobutanecarboxylate (10): Benzyl 1-{[4-formyl-4-(methoxymethyl)piperidin-1- yl]methyl}cyclobutanecarboxylate (7) (136.10 g, 378.62 mmol) and (lR,2S)-2- phenylcyclopropanamine (8) (61.0 g, 458.0 mmol) were mixed in methylene chloride (1225 mL). The mixture was then concentrated under vacuum with a bath temperature of 40 °C. The oily residue was re-dissolved in methylene chloride (1225 rnL). The solution was then concentrated under vacuum with a bath temperature of 40 °C. The formation of imine was confirmed by LC-MS at pH 10. The residue was dissolved in methylene chloride (1225 mL), acetic acid (45.1 mL, 793.0 mmol) was added, followed by sodium triacetoxyborohydride (79.4 g, 793.0 mmol). The mixture was stirred for 1.5 hours. HPLC indicated the completion of the reaction. Methylene chloride (1225 rnL) was added to dilute the reaction. To the mixture was added 7% aqueous sodium bicarbonate (2449.6 g), the mixture was stirred for 30 minutes and DCM phase was collected. The organic phase was washed with aqueous 7% sodium bicarbonate (2449.6 g), then concentrated under vacuum to about 1300-1500 rnL volume, and used directly for the next step. To the above solution was added di-tert-butyldicarbonate (180.0 g, 377.63 mmol). The mixture was stirred at room temperature overnight. To the reaction mixture was added 67 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 aqueous 7% sodium bicarbonate and after stirring for 30 minutes, the organic phase was collected, dried over MgSO4 and concentrated. The residue was purified by Biotage (0-20% ethyl acetate in hexane, checked by anisaldehyde as stain) to give compound (10) (190.0 g, 87.2%). Compound (9): LC-MS calculated for C30H40N2O3 [M+H]+ m/z: 477.3; found 477.3. 'H NMR (400 MHz, D2O) 5 7.49- 7.23 (m, 8H), 7.18 (d, J= 7.3 Hz, 2H), 5.23 (s, 2H), 3.56 (s, 2H), 3.34 (s, 3H), 3.23 (s. 2H), 3.16 (s. 3H), 3.01 (s, 2H), 2.48 (dt, J= 11.2, 8.1 Hz, 3H), 2.17 - 1.93 (m, 4H), 1.55- 1.49 (m, 5H), 1.37 (q, J= 7.2 Hz, 1H). Compound (10): LC-MS calculated for C35H48N2O5|M+H|1 m/z: 577.3; found 577.3. *H NMR (400 MHz, CD3CN) 8 7.46 - 7.23 (m, 8H), 7.15 (dd,J =28.9, 7.3 Hz, 2H), 5.15 (s, 2H), 3.44 (d, J= 14.5 Hz, 1H), 3.31 - 3.07 (m, 5H), 2.78- 2.67 (m, 3H), 2.43 (dd, J= 11.1, 5.8 Hz, 4H), 2.26 (ddd, J= 24.0, 11.7, 4.7 Hz, 4H), 2.08- 1.95 (m, 4H), 1.86 (p, J= 7.3, 6.6 Hz, 2H), 1.55 - 1.44 (m, 1H), 1.44- 1.28 (m, 13H), 1.21 (dq, J = 13.5, 6.8 Hz, 1H). Compound (10) can also be purified by reacting compound (10) with L-tartaric acid in the presence of isopropanol, methanol, and n-heptane to form compound (10) L-tartrate and reacting compound (10) L-tartrate with NaHCOs in dichloromethane to provide purified compound (10). The corresponding salt formation and neutralization procedures are described below. Crude compound 10 and 2-propanol are stirred at 15 - 30 °C for about 15 minutes until a solution is obtained. /.-Tartaric acid and methanol are stirred at 15 - 30 °C for about 1 hour until a solution is obtained. The /.-tartaric acid solution is then added to the solution of crude compound 10 and the reaction mixture is stirred at 15 - 30 °c for about 1 hour, nHeptane is then added to the reaction mixture and the resulting mixture is stirred at 15 - 30 °C for about 1 hour. The reaction mixture is filtered and the wet cake is washed with n-heptane and dried to afford the corresponding L-tartaric acid salt of compound 10. Dichloromethane (DCM) and L-tartaric acid salt of compound 10 are charged to a reactor at ambient temperature, and aqueous NaHCOs solution is charged to the reactor while maintaining the reaction mixture at no more than 30 °C. The reaction mixture is stirred at 15 - 30 °C for about 30 minutes and the phases are separated. The organic phase is concentrated under reduced pressure until the distillation stops. The distillation residue is then treated with ethanol (EtOH) and the resulting solution of compound 10 in ethanol (EtOH) is directly used in the subsequent reaction without further purification. 68 5 10 15 20 25 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 Step 9. Synthesis of lf[4-({(tert-butoxycarbonyl)[(lR,2S)-2-phenylcyclopropyl]amino}methyl)-4- (methoxymethyl)piperidin-l-yl]methyl}cyclobutanecarboxylic acid (11): Benzyl 1-{[4-({(tert-butoxycarbonyl)[(lR,2S)-2-phenylcyclopropyl]amino}methyl)- 4-(methoxymethyl)piperidin-l-yl]methyl}cyclobutanecarboxylate (10) (449.10 g, 778.65 mmol) was dissolved in ethanol (1570 mL). The solution was concentrated in vacuo with a bath temperature at 40 °C. The residue was again dissolved in ethanol (1570 mL) and the solution was concentrated using in vacuo with bath temperature at 40 °C. To the residue was added a solution of potassium hydroxide (89.9 g, 1604 mmol) in ethanol (1570 mL) and water (224.6 mL). The mixture was then heated in a bath at 40 °C. HPLC indicated the reaction was complete (PCT 0.5%) after 8 hours. A vacuum was applied to remove ethanol, then water was added (2000 mL), the mixture concentrated down, and then the process was repeated one more time to yield crude product. Water (1570 mL), 2-methoxy-2-methylpropane (2246 mL) and sodium chloride (200.0 mL) were added to the crude product. The organic layer was then collected, and concentrated. The residue was re-dissolved in water (2000 mL), and then concentrated to dryness. The residue was re-dissolved in water (2000 mL) and the solution was washed again with 2-methoxy-2-methylpropane (2246 mL). The repeated washing with MTBE was performed until the benzyl alcohol was less than 0.5% in aqueous layer. The aqueous solution was then cooled in an ice bath before being treated dropwise with an aqueous HC1 solution, made from the concentrated hydrochloric acid (cone. HC1, 95.0 g, 951 mmol) and water (450.0 g), until pH 5. The mixture was extracted with methylene chloride (3000 mL x 2) twice. The combined DCM layers were concentrated to give the desired product (11) as a white solid, which was used directly in the next step. LC-MS calculated for C28H42N2O5 [M+H]+ m/z: 487.3; found 487.3. '1 I NMR (400 MHz, CD3CN) 5 7.29 (t, J= 7.5 Hz, 2H), 7.17 (dd, J = 69 5 10 15 20 25 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 24.1, 7.3 Hz, 3H), 3.53 (d, J = 14.4 Hz, 1H), 3.34- 3.14 (m, 5H), 3.01- 2.73 (m, 7H), 2.43- 2.36 (m, 2H), 2.21- 1.82 (m, 7H), 1.79- 1.58 (m, 4H), 1.38 (s, 9H), 1.23 (q, J = 6.5 Hz, 1H). Step 10. Synthesis of l-{[4-(methoxymethyl)-4-({[(lR,2S)-2- phenylcyclopropyl]amino}methyl)piperidin-l-yl]methyl}cyclobutanecarboxylic acid bis(4- methylbenzenesuljdnate) (12): ,2TsOH TsOH, THF compound (I) di-tosylate sait l-{[4-({(tert-Butoxycarbonyl)[(lR,2S)-2-phenylcyclopropyl]amino}methyl)-4- (methoxymethyl)piperidin-l-yl]methyl}cyclobutanecarboxylic acid (11) (370.0 g, 722.4 mmol) was dissolved in tetrahydrofuran (2000.0 mL). To the solution was added ptoluenesulfonic acid monohydrate (300.0 g, 1577 mmol). The mixture was heated to 55- 60°C. In 14 hours, HPLC indicated the reaction was complete (SM<1%). To the mixture while heating was added 2-methoxy-2-methylpropane (4000 mL) through an addition funnel. The reaction mixture was kept stirring for 6 hours at 55°C-60°C before disconnection of the heat. The mixture was cooled down to room temperature and stirred overnight. Solid product was collected by filtration and the cake was washed with 2-methoxy-2- methylpropane (1000 mL) twice, and dried on the filter overnight. The material l-{[4- (methoxymethyl)-4-({[(1R,2S)-2-phenyIcyclopropy1]amino}methyl)piperidin-1- yl]methyl}cyclobutanecarboxylic acid bis(4-methylbenzenesulfonate) (12) also known as 1- {[4-(methoxymethyl)-4-({[(lR,2S)-2-phenylcyclopropylJamino}methyl)piperidin-lyl]methyl}cyclobutanecarboxylic acid ditosylate salt was used directly for recrystallization. Step 11. Crystalline Form I of l-{[4-(methoxymethyl)-4-({[(lR,2S)-2- phenylcyclopropyl]amino}methyl)piperidin-l-yl]methyl}cyclobutanecarboxylic acid bis(4- methylbenzenesulfonate (Compound I di-tosylate salt, Form I) 70 5 10 15 20 25 84193183 l-{[4-(Methoxymethyl)-4-({|(lR,2S)-2-phenylcyclopropyl]amino}rnethyl)piperidinl-yl]methyl}cyclobutanecarboxylic acid bis(4-methylbenzenesulfonate) (12) (532.9 g, 729.1 mmol) was mixed with 2-butanone (7223 mL). The mixture was heated to 55°C (internal temperature set) to become a clear solution. The hot solution was polish filtered through an inline filter, and the clear solution was distilled off under vacuum to about 4 L volume while being heated at 55 °C (internal temperature set). To the solution was added heptane (4676 mL) while stirring. After the addition, the mixture was kept at 55 °C (internal temperature set) for 4 hours, then allowed to cool to room temperature. The mixture was stirred overnight. The solid was filtered and washed with a mixture of heptane (1000.0 mL) and 2-butanone (1000.0 mL). The recrystallized product l-{[4- (methoxymethyl)-4-({[(lR,2S)-2-phenyIcyclopropyl]amino}methyl)piperidin-lyl]methyl}cyclobutanecarboxylic acid bis(4-methylbenzenesulfonate) (12) was dried on the filter overnight, and then under high vacuum at 50 °C overnight to give pure product. LC-MS calculated for C37H50N2O9S2 [M+H]+ m/z: 387.2; found 387.2. ‘H NMR (400 MHz, MeOD) 5 7.73 (d, J= 8.2 Hz, 4H), 7.34- 7.19 (m, 7H), 7.15 (d, J=12 Hz, 2H), 3.70- 3.51 (m, 4H), 3.43 (d, J= 18.4 Hz, 7H), 3.36- 3.22 (m, 3H), 3.13- 2.97 (m, 1H), 2.67- 2.50 (m, 3H), 2.38 (s, 6H), 2.21 (q, J= 9.5, 8.6 Hz, 2H), 2.05 (dt, J= 28.5, 11.6 Hz, 2H), 1.94-1.78 (m, 1H), 1.66- 1.55 (m, 1H), 1.32 (d, J= 8.0 Hz, 2H), 0.92 (t, J= 6.8 Hz, 1H). Example 2. X-Ray Powder Diffraction (XRPD) of Form I Form I was characterized by XRPD. The X-Ray Power Diffraction (XRPD) was obtained from Rigaku MiniFlex™ X-ray Powder Diffractometer (XRPD). The general experimental procedures for XRPD were: (1) X-ray radiation from copper at 1.054056 Â with Kp filter; (2) X-ray power at 30 KV, 15 mA; and (3) the sample powder was dispersed on a zero-background sample holder. The general measurement conditions for XRPD were: Start Angle 3 degrees; Stop Angle 45 degrees; Sampling 0.02 degrees; and Scan speed 2 degree/min. The XRPD pattern is shown in Figure 1 and the XRPD data are provided in Table 1. Date Reçue/Date Received 2023-01-27 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 Table 1 2-Theta (°) Height H% 3.6 460 70 4.9 608 92.5 6.2 658 100 7.7 326 49.6 8.9 116 17.6 10.0 128 19.5 11.5 132 20.1 13.8 42 6.3 14.3 51 7.8 15.0 98 14.9 15.5 105 15.9 16.3 123 18.7 17.1 49 7.4 17.8 170 25.8 19.1 163 24.8 19.8 108 16.4 20.9 202 30.8 22.2 170 25.9 22.7 408 62 23.1 133 20.3 23.9 49 7.5 24.4 94 14.3 24.9 73 11 25.8 65 9.9 27.2 55 8.4 28.7 43 6.5 29.1 53 8.1 30.6 47 7.1 31.2 70 10.6 32.8 59 9 38.4 39 5.9 39.6 35 5.4 43.9 36 5.5 Example 3. 5 Differential Scanning Calorimetry (DSC) thermogram of Form I Form I was characterized by DSC. The DSC was obtained from TA Instruments Differential Scanning Calorimetry, Model Q200 with autosampler. The DSC instrument conditions were as follows: 30 - 300°C at 10°C/min; Tzero aluminum sample pan and lid; and 72 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 nitrogen gas flow at 50 mL/min. The DSC thermogram is shown in Figure 2. The DSC thermogram revealed a major endothermal event at an onset temperature of 94.6 °C with a peak temperature of 103.1°C which is believed to be the melting of the compound. Example 4. Thermogravimetric Analysis (TGA) of Form I Form I was characterized by TGA. The TGA was obtained using a TA Instrument Thermogravimetric Analyzer, Model Q500. The general experimental conditions for TGA were: ramp from 20°C to 600 °C at 20°C/min; nitrogen purge, gas flow at 40 mL/min followed by balance of the purge flow; sample purge flow at 60 mL/min; platinum sample pan. The TGA thermogram is shown in Figure 3. A weight loss of about 3.5% up to 150°C was observed and believed to be associated with the loss of moisture and residual solvents. The compound started to decompose significantly after 200 °C. Example 5. Dynamic Vapor Sorption (DVS) Analysis of Form I Form I was characterized by DVS. The DVS analysis was performed on aTA Instruments Vapor Sorption Analyzer, model VTI-SA+. The sample was pre-dried on VTI at 50 °C with 0%RH N2 for 1 h. Then the moisture uptake profile was completed in one cycle in 5%RH increments with adsorption from 0%RH to 95% RH followed by desorption in 5% increments from 95% to 5% RH. The equilibration criteria were 0.0050 wt% in 5 minutes with a maximum equilibration time of 180 minutes. All adsorption and desorption were performed at 25 °C. The adsorption/desorption isotherm is shown in Figure 16. Form I is hygroscopic and can change to different hydrates under different conditions. Example 6. Preparation and Characterization of Form HI Form HI of Compound I di-tosylate salt was prepared during the process of drying a wet sample of Compound I di-tosylate salt, Form I, under ambient conditions. Form I slowly absorbed atmospheric moisture and gradually changed to crystalline Form HI. Under storage 73 84193183 conditions of 25 °C/60%RH and 40 °C/75%RH, Form I was also converted to Form HI. Form HI can also be generated by purging humidified air (e.g., 60-85%RH) through Form I solid. Form HI was characterized by XRPD. The X-Ray Powder Diffraction (XRPD) was obtained from Broker D2 PHASER™ X-ray Powder Diffractometer (XRPD) instrument. The 5 general experimental procedures for XRPD were: (1) X-ray radiation from copper at 1.054056 Â with Kp filter and LYNXEYE™ detector; (2) X-ray power at 30 KV. 10 mA; and (3) the sample powder was dispersed on a zero-background sample holder. The general measurement conditions for XRPD were: Start Angle 5 degrees; Stop Angle 30 degrees; Sampling 0.015 degrees; and Scan speed 2 degree/min. The XRPD pattern is shown in Figure 10 4 and the XRPD data are provided in Table 2.Table 2 74 2-Theta (°) Height H% 7.0 4354 77.6 8.9 886 15.8 9.3 1185 21.1 10.4 3139 55.9 10.7 660 11.8 11.5 51 0.9 12.0 151 2.7 13.6 2036 36.3 14.1 491 8.7 14.4 124 2.2 15.5 4512 80.4 16.2 857 15.3 16.6 2374 42.3 17.3 4304 76.7 17.9 1242 22.1 18.7 2547 45.4 19.8 3854 68.7 20.2 3439 61.3 20.5 2144 38.2 20.8 4164 74.2 21.4 1389 24.8 21.7 2735 48.7 22.2 4344 77.4 23.1 2229 39.7 24.0 5611 100 24.7 126 2.2 25.3 786 14.0 25.5 1072 19.1 Date Reçue/Date Received 2023-01-27 5 10 15 20 25 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 26.0 379 6.8 26.7 730 13.0 27.3 340 6.1 28.2 1649 29.4 28.8 246 4.4 29.2 144 2.6 Form HI was characterized by DSC. The DSC was obtained from TA Instruments Differential Scanning Calorimetry, Model Q2000 with autosampler. The DSC instrument conditions were as follows: 25 - 150°C at 10°C/min; Tzero aluminum sample pan and lid; and nitrogen gas flow at 50 mL/min. The DSC thermogram is shown in Figure 5. The DSC thermogram revealed a major endothermal event at an onset temperature of 73.5 °C with a peak temperature of 79.8°C which is believed to be a dehydration event. Form HI was characterized by TGA. The TGA was obtained using a PerkinElmer Thermogravimetric Analyzer, Model Pyris 1. The general experimental conditions for TGA were: ramp from 25°C to 200 °C at 10°C/min; nitrogen purge gas flow at 60 mL/min; ceramic crucible sample holder. The TGA thermogram is shown in Figure 6. A weight loss of about 5.3% up to 110°C was observed and believed to be associated mostly with the loss of water. Form HI was characterized by DVS. The DVS analysis was performed on a TA Instruments Vapor Sorption Analyzer, model VTI-SA+. The moisture uptake profile was completed in one cycle in 5%RH increments with adsorption from 35%RH to 95% RH followed by desorption in 5% increments from 95% to 5% RH. The equilibration criteria were 0.0010 wt% in 5 minutes with a maximum equilibration time of 180 minutes. All adsorption and desorption were performed at 25°C. No pre-drying step was applied for the sample. The adsorption/desorption isotherm is shown in Figure 17. Form HI is slightly hygroscopic. It can absorb more water at high humidity and can be de-hydrated at low humidity. Example 7. Preparation and Characterization of Form HII 75 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 Form HII was prepared by slurring of Form I in water for 3 days at room temperature. The resulted suspension was filtered. The residual solid was collected and air dried for 5-7 days at ambient condition. Form HII was characterized by XRPD. The XRPD was obtained from Bruker D2 5 PHASER X-ray Powder Diffractometer instrument. The general experimental procedures for XRPD are similar to those for Form HI. The XRPD pattern is shown in Figure 7 and the XRPD data are provided in Table 3. Table 3 2-Theta (°) Height H% 6.5 902 21.6 6.9 1739 43.0 8.0 74.7 1.8 8.7 2372 56.9 10.1 4023 96.5 10.9 212 5.1 12.8 103 2.5 13.7 717 17.2 14.3 2944 70.6 14.8 3399 81.5 15.5 699 16.8 15.6 662 15.9 15.9 873 20.9 16.0 808 19.4 16.5 526 12.6 16.9 1215 29.1 17.4 2487 59.6 17.7 2644 63.4 18.2 2023 48.5 19.3 195 4.7 20.0 1888 45.3 20.5 3037 72.8 20.6 2694 64.6 21.3 3226 77.4 22.1 2317 55.6 22.0 3129 75.0 22.7 4170 100 23.2 1453 34.8 23.5 1263 30.3 24.3 3560 85.4 24.6 2153 51.6 25.1 804 19.3 25.4 792 19.0 76 5 10 15 20 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 26.1 594 14.2 27.1 817 19.6 27.6 184 4.4 28.4 2374 56.9 29.5 290 7.0 Form HII was characterized by DSC. The DSC was obtained from TA Instruments Differential Scanning Calorimetry, Model Q2000 with autosampler. The DSC instrument conditions are similar to those for Form HI. The DSC thermogram is shown in Figure 8. The DSC thermogram revealed a major endothermal event at an onset temperature of 49.0 °C with a peak temperature of 52.3°C which is believed to be the dehydration of the compound. Form HII was characterized by TGA. The TGA was obtained from PerkinElmer Thermogravimetric Analyzer, Model Pyris 1. The general experimental conditions for TGA are similar to those for Form HI. The TGA thermogram is shown in Figure 9. A weight loss of about 11.3% up to 120°C was observed and is believed to be associated mostly with the loss of water. Example 8. Preparation and Characterization of Form Hill Form Hill was prepared by drying Form HI on Vapor Sorption Analyzer (TA Instruments VTI-SA+) at 40 °C with 0 %RH N2 for 3 h and then exposing it to humidity at about 30-50 %RH at 25 °C for 1 day. Form Hill can change to Form HI when it is further exposed to high humidity at about 60-85 %RH. Form Hill was characterized by XRPD. The XRPD was obtained from Bruker D2 PHASER X-ray Powder Diffractometer (XRPD) instrument. The general experimental procedures for XRPD are similar to those for Form HI. The XRPD pattern is shown in Figure 10 and the XRPD data are provided in Table 4. Table 4 2-Theta (°) Height H% 7.0 1719 31.2 8.6 86.6 1.6 9.0 2232 40.5 9.2 2435 44.1 10.2 3550 64.4 10.6 110 2.0 77 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 11.7 481 8.7 13.1 1671 30.3 13.5 99.6 1.8 13.9 150 2.7 14.3 269 4.9 15.0 1698 30.8 15.6 1398 25.3 16.2 742 13.4 16.3 443 8.0 17.1 1989 36.1 17.4 2147 38.9 17.9 2597 47.1 18.4 519 9.4 18.9 1756 31.8 19.8 475 8.6 20.3 4956 89.8 20.9 842 15.3 22.0 4791 86.9 22.5 736 13.3 22.9 635 11.5 23.4 603 10.9 23.5 826 15.0 23.8 5517 100 24.0 1063 19.3 24.6 453 8.2 25.2 849 15.4 25.5 580 10.5 26.2 778 14.1 26.5 854 15.5 27.5 603 10.9 28.1 515 9.3 28.9 2297 43.5 29.1 210 3.8 29.8 101 1.8 Form Hill was characterized by DSC. The DSC was obtained from TA Instruments Differential Scanning Calorimetry, Model Q2000 with autosampler. The DSC instrument conditions are similar to those for Form HI. The DSC thermogram is shown in Figure 11. 5 The DSC thermogram revealed two major endothermal events. The first event appeared at an onset temperature of 54.3 °C with a peak temperature of 66.8°C which is believed to be the dehydration of the compound. The second event appeared at an onset temperature of 92.6 °C with a peak temperature of 98.4°C which is believed to be the melting of the compound. 78 84193183 Form Hill was characterized by TGA. The TGA was obtained from PerkinElmer™ Thermogravimetric Analyzer, Model Pyris™ 1. The general experimental conditions for TGA are similar to those for Form HI. The TGA thermogram is shown in Figure 12. A weight loss of about 4.8% up to 120°C was observed and is believed to be associated mostly with the 5 loss of water. Example 9. Preparation and Characterization of Form DH Form DH was prepared by drying Form HI on Vapor Sorption Analyzer (TA 10 Instruments VTI-SA+) at 25 °C with 0%RH N2 for 2 days. When Form DH is exposed to humidity, it can absorb water and change to Form Hill at about 30-50 %RH or to Form HI at high humidity around 60-85 %RH Form DH was characterized by XRPD The XRPD was obtained from Bruker D2 PHASER X-ray Powder Diffractometer (XRPD) instrument. The general experimental 15 procedures for XRPD are similar to those for Form HI. The XRPD pattern is shown in Figure 13 and the XRPD data are provided in Table 5. Table 5 79 2-Theta (°) Height H% 5.6 57.5 1.0 6.1 69.2 1.2 6.6 62.7 1.1 7.4 2956 50.0 7.5 3560 60.2 9.6 2326 39.4 10.0 534 9.0 10.7 4068 68.8 12.0 128 2.2 12.6 95.4 1.6 13.6 217 3.7 13.9 1487 25.2 14.8 1943 32.9 15.5 780 13.2 16.0 533 9.0 16.1 311 5.3 16.6 450 7.6 17.2 1437 24.3 17.3 1675 28.3 18.1 1061 18.0 Date Reçue/Date Received 2023-01-27 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 18.3 1500 25.4 18.9 282 4.8 19.5 61.7 1.0 20.1 1482 25.1 20.7 1423 24.1 21.6 1585 26.8 22.1 936 15.8 22.9 5909 100 23.4 588 10.0 24.0 955 16.2 24.7 3283 55.6 25.3 94.8 1.6 25.8 754 12.7 26.7 721 12.2 27.1 433 7.3 28.0 335 5.7 28.2 322 5.4 29.5 200 3.4 Form DH was characterized by DSC. The DSC was obtained from TA Instruments Differential Scanning Calorimetry, Model Q2000 with autosampler. The DSC instrument conditions similar to those for Form HI. The DSC thermogram is shown in Figure 14. The 5 DSC thermogram revealed one major endothermal event at an onset temperature of 93.8 °C with a peak temperature of 97.5°C which is believed to be the melting of the compound. Form DH was characterized by TGA. The TGA was obtained from PerkinElmer Thermogravimetric Analyzer, Model Pyris 1. The general experimental conditions for TGA are similar to those for Form HI. The TGA thermogram is shown in Figure 15. A weight 10 loss of about 2.3% up to 120 °C was observed and is believed to be associated mostly with the loss of water. Form DH was characterized by DVS. The DVS analysis was performed on a TA Instruments Vapor Sorption Analyzer, model VTI-SA+. Form DH was generated by pre¬ drying Form HI on VTI at 40°C with 0%RH N2 for 3 h. Then the moisture uptake profile was 15 completed in one cycle in 5%RH increments with adsorption from 0%RH to 95% RH followed by desorption in 5% increments from 95% to 85% RH. The equilibration criteria were 0.0010 wt% in 5 minutes with a maximum equilibration time of 180 minutes. All adsorption and desorption were performed at 25 °C. 80 5 10 15 20 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 The adsorption/desorption isotherm is shown in Figure 18. Form DH is hygroscopic and will absorb water stepwise to form different hydrates. The solid collected after DVS at 85%RH is characterized as Form HI. Example 10. Physical Stability of Form HI Physical stability of Form HI was studied under different humidity conditions. The humidity was controlled at 25 °C using Vapor Sorption Analyzer (TA Instruments, Model VTI-SA+). Approximately 20 mg of Form HI in the sample holder was placed inside the humidity chamber of the instrument and held under constant humidity. A sample in an open glass vial was also set up under ambient conditions. After a certain period of time, the sample was removed and characterized by XRPD, DSC, and TGA. Weight loss by TGA was mostly associated with loss of water. The experimental parameters of XRPD, DSC, and TGA are analogous to those in Example 6 for Form HI. Form HI was stable for 10 days under humidity conditions of 10-85%RH and was stable for 60 days under ambient conditions. Form HI was de-hydrated below 10%RH and absorbed water to change to Form HII at 90%RH. The table below provides the data for the physical stability of Form HI at 25 °C (open vial). Table 6 Humidity (%RH) Time(Day) DSC (°C) %Wt Loss by XRPD (Peak Temperature)TGA (25-120°C) 0 2 97.5 2.30 Form DH 5 7 81.2 2.93 Form HI 10 10 82.4 5.05 Form HI 30 5 80.7 5.38 Form HI 75 10 79.8 5.30 Form HI 85 10 79.9 5.35 Form HI 90 4 80.0 6.04 Form HI + Form HII (minor) 10 55.7; 79.1 9.4 Form FormHI HII+ Ambient 60 79.8 4.77 Form HI Example 11. Phase Equilibration at 25 °C and 50 °C 81 5 10 15 20 25 30 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 To a solvent such as chloroform, dimethylformamide (DMF), 1,4-dioxane, methyl isobutyl ketone (MIBK), tetrahydrofiiran (THF), acetone, n-BuOH, isobutyl acetate, isopropyl acetate (IPAc), isopropyl alcohol (IPA), water, methyl ethyl ketone (MEK), methanol, 2-methoxyethanol, EtOH, ethyl acetate (EtOAc), ethyl formate, isobutyl acetate, heptane or 1-propanol was added Compound I di-tosylate until a cloudy solution was obtained, then about 30 mg of Compound I di-tosylate was added to the cloudy solution. The mixture was stirred at 25 °C for 3 days and at 50 °C for 2 days. The solid was filtered and analyzed by XRPD and characterized by DSC and TGA. Phase equilibration at 25 °C resulted in Form II (n- BuOH), Form III (IPA), Form IV (water), and amorphous (1,4- dioxane). Example 12. Evaporation at 25 °C and 50 °C Evaporation studies of Compound I di-tosylate solutions were carried out in various solvents such as acetonitrile (MeCN), chloroform, dichloromethane, DMF, 1,4-dioxane, methanol, 2-methoxyethanol. MIBK, THF, acetone, n-BuOH, methyl t-butyl ether (MTBE), dimethylsulfoxide (DMSO), EtOH, EtOAc, ethyl formate, isobutyl acetate, IPAc, 1-propanol, water, and MEK at 25 ± 1 °C. Form IV (water), Form V (MeCN, 1-propanol), Form VI (CH2CI2), and Form VII (EtOH) were discovered. Evaporation at 50 ± 1 °C in the above solvents resulted in Form V (MeCN, EtOH, and 1-propanol), Form VI (2-methoxyethanol and IPA), and Form VIII (w-BuOH). Example 13. Anti-solvent addition Saturated or almost saturated solutions of Compound I di-tosylate were prepared by adding Compound I di-tosylate to the solvents in Table 7 below. An anti-solvent, such as MTBE, IPAc, heptane, and hexane was added to induce precipitation. The results are presented in Table 7. Anti-solvent addition resulted in Form II (h-BuOH/IPAc), Form III (IPA/hexane, IPA/MTBE, and I PA heptane). Form Illa (EtOH/IPAc), Form V (MeCN/MTBE and MeCN/IPAc), Form IX (n-BuOH/MTBE and n-BuOH/heptane), Form X (EtOH/heptane) and amorphous (THF/MTBE, THF/heptane, THF/hexane, MEK/heptane, and MEK hexane). 82 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 Table 7. Precipitation from Anti-solvent addition Solvent (mL) Anti-solvent (mL) Form MeCN (0.3) MeCN (0.3) THF* (1.5) THF* (1.0) THF* (1.0) n-BuOH** (0.4) n-BuOH** (0.4) n-BuOH** (0.4) EtOH*** (0.3) EtOH*** (0.4) IPA (1.0) IPA(l.O) IPA(l.O) MEK* (1.5) MEK* (1.5) *about 45 °C saturated solution MTBE (2.0) IPAc (2.0) MTBE (3.0) Heptane (1.8) Hexane (1.5) MTBE (3.5) Heptane (3.0) IPAc (3.0)Heptane (2.5) IPAc (3.0) Hexane (6.0) MTBE (9.0) Heptane (6.0) Heptane (1.8) Hexane (1.8) VVamorphousamorphousamorphousIXIX XIllaIIIIIIIIIAmorphousAmorphous **about 50 mg/mL of n-BuOH solution ***about 60 mg/mL of ethanol solution 5 ****25 min stirring to give slurry Example 14. Reverse Addition 10 Saturated solutions of Compound I di-tosylate were prepared in solvents listed in Table 8 and were added to a larger volume of a miscible anti-solvent. Reverse addition resulted in Form II (w-BuOH/IPAc), Form III (IPA/hexane, IPA/MTBE, and IPA/heptane), Form Illa (EtOH/IPAc), Form V (MeCN/MTBE and MeCN/IPAc), Form IX (nBuOH/MTBE and w-BuOH/Heptane), and Form X (EtOH/heptane). Table 8. Precipitation from Reverse addition 83MTBE (3.0) IPAc (0.5) MTBE (2.0) Heptane (2.0) MeCN (0.5) MeCN (0.5) n-BuOH** (0.3) n-BuOH** (0.3) VVIXIX Solvent (mL) Anti-solvent (mL) Form 5 10 15 20 25 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 n-BuOH** (0.3) EtOH*** (0.3) EtOH*** (0.4) IPA (0.6) IPA (0.6) IPA (0.6) *about 45 °C saturated solution IPAc (3.5) Heptane (2.5) IPAc (3.0) Hexane (3.0) MTBE (3.0) Heptane (3.0) JJ #**XIllaIIIIIIIII **about 50 mg/mL of n-BuOH solution ***about 60 mg/mL of ethanol solution ****25 min stirring to give slurry Example 15. Quench Cool of Saturated Solution Saturated solutions prepared at 35 °C were quench-cooled to about -20 °C to -25 °C. The results are shown in Table 9. Quench cooling resulted in Form II (h-BuOH), Form III (IPA), Form V (MeCN), and Form XI (1-propanol). Table 9. Polymorphism Identification from Quench Cool Solvent Solid State Form MeCN V n-BuOH II 1-Propanol XI IPA III Example 16. Crystallization of Saturated Solution with Heating and Cooling Cycles Saturated solutions of Compound I di-tosylate were prepared at 50 °C, and cooled in a bath slowly by using a programmed circulating bath. To the clear solution of Compound I di-tosylate was added about 20-30 mg of Compound I di-tosylate Form I to give a slurry. The formed slurry was then heated to 50 °C over 2 hours and then cooled down to 5 °C over 2 hours. This process was repeated for 3 days and the resulting solid was filtered for further analysis. The results are in Table 10. Heating and cooling resulted in Form I (EtOAc, MEK, and MEK/heptane), Form IV (water), and Form XII (acetone and IPA). Table 10. Crystallization of Saturated Solution 84 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 Solvent Solid State Form Acetone XII Ethyl acetate I IPA XII Water IV MEK I MEK/Heptane (2:1) I Example 17. Preparation and Characterization of Form II In one experiment. Form II was prepared by adding about 60 mg of Form I to 3 mL of 5 saturated or cloudy solution of Form I in n-butanol. The resulting mixture was stirred at 25 ± 1 °C for 3 days. The resulting solid was filtered. Form II was also prepared in accordance with the procedures set forth in Examples 13,14 and 15 in n-BuOH/IPAc, w-BuOHIPAc and n-BuOH, respectively. Form II was characterized by XRPD. The XRPD was obtained using similar 10 conditions as those for Form I. The XRPD pattern is shown in Figure 19 and the XRPD data are provided in Table 11. Table 11 2-Theta 5.1 Height 265 H%17.3 6.8 930 60.5 9.0 46 3.0 10.2 207 13.5 14.2 229 14.9 15.8 213 13.9 17.7 219 14.3 20.4 477 31.1 22.0 220 14.3 23.3 1536 100 24.3 301 19.6 26.9 564 36.7 28.5 54 3.5 29.3 69 4.5 30.1 205 13.3 30.8 86 5.6 33.6 88 5.7 35.6 79 5.1 39.0 61 4.0 85 5 10 15 20 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 41.5 81 5.3 44.2 45 2.9 Form II was characterized by DSC. The DSC was obtained using similar conditions as those for Form I. The DSC thermogram is shown in Figure 20. The DSC thermogram revealed an endothermic event at an onset temperature of 74.0 °C with a peak temperature of 77.8 °C and an exothermic event with an onset temperature 149.3 °C with a peak temperature of 185.0 °C. Form II was characterized by TGA. The TGA was obtained using similar conditions as Form I. The TGA thermogram is shown in Figure 21. Example 18. Preparation and Characterization of Form III In one experiment, Form III was prepared by adding about 50 mg of Form I to about 3 mL of saturated or cloudy solution of Form I in IPA followed by stirring at 25 ± 1 °C for 3 days. The resulting solid was filtered. Form III was also prepared according to the procedures set forth in Examples 13, 14 and 15 using IPA/hexane, IPA/heptane or IPA/MTBE as a solvent pair in antisolvent addition; IPA/hexane, IPA/MTBE or IPA/heptane as a solvent pair in reverse addition; and IPA in quench cooling. Form III was characterized by XRPD. The XRPD was obtained using similar conditions as those for Form I. The XRPD pattern is shown in Figure 22 and the XRPD data are provided in Table 12. Table 12 2-Theta 4.6 Height 2943 H%70.2 5.2 4194 100 6.5 203 4.8 8.2 141 3.4 9.2 299 7.1 10.3 234 5.6 11.4 32 0.8 14.0 304 7.2 15.4 160 3.8 16.3 287 6.8 18.4 390 9.3 18.9 59 1.4 86 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 19.6 183 4.4 20.2 46 1.1 20.7 188 4.5 22.2 222 5.3 22.8 1027 24.5 24.2 565 13.5 26.4 110 2.6 27.4 94 2.2 28.0 40 1.0 29.2 54 1.3 30.9 118 2.8 32.7 44 1.0 33.1 60 1.4 37.5 33 0.8 42.5 31 0.7 Form III was characterized by DSC. The DSC was obtained using similar conditions as those for Form I. The DSC thermogram is shown in Figure 23. The DSC thermogram revealed an endothermic event at an onset temperature of 73.5 °C with a peak temperature of 5 79.6 °C and an exothermic event with an onset temperature 152.5 °C with a peak temperature of 181.0 °C. Form III was characterized by TGA. The TGA was obtained using similar conditions as Form I. The TGA thermogram is shown in Figure 24. 10 Example 19.Preparation and Characterization of Form Illa In one experiment. Form Illa was prepared by adding 0.4 mL of saturated solution of Form I in ethanol (60 mg/rnL) to 3.0 mL of IPAc. The resulting solid was filtered. Form Illa was also prepared according to the procedure set forth in Example 13 using EtOH/IPAc as a 15 solvent pair. Form Illa was characterized by XRPD. The XRPD was obtained using similar conditions as those for Form I. The XRPD pattern is shown in Figure 25 and the XRPD data are provided in Table 13. Table 13 2-Theta Height H% 4.5 1206 56.7 5.1 2128 100 87 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 6.9 856 40.2 8.1 400 18.8 9.2 138 6.5 10.1 537 25.2 11.3 88 4.1 13.5 183 8.6 14.1 140 6.6 14.6 59 2.8 15.2 144 6.8 16.3 359 16.9 17.8 229 10.8 18.3 185 8.7 19.4 132 6.2 20.8 484 22.7 21.4 230 10.8 22.2 559 26.3 22.7 1493 70.2 24.1 756 35.5 25.2 81 3.8 25.7 58 2.7 26.4 140 6.6 27.3 125 5.9 29.1 91 4.3 30.7 70 3.3 31.4 48 2.3 32.9 57 2.7 Example 20. Preparation and Characterization of Form IV In one experiment, Form IV was prepared by adding about 50 mg of Form I to about 3 5 mL of saturated or cloudy solution of Form I in water followed by stirring at 25 ± 1 °C for 3 days. The resulting solid was filtered and air-dried in hood for 4 days. Form IV was also prepared according to the procedures set forth in Examples 12 and 16 using water as a solvent. Form IV was characterized by XRPD. The XRPD was obtained using similar 10 conditions as those for Form I. The XRPD pattern is shown in Figure 26 and the XRPD data are provided in Table 14. 88 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 Table 14 2-Theta 7.1 Height 186 H%93.5 8.9 63 31.7 10.5 70 35.2 14.6 100 50.3 15.2 55 27.6 18.0 107 53.8 18.5 63 31.7 20.6 102 51.3 20.9 123 61.8 21.7 68 34.2 22.3 61 30.7 23.1 199 100 24.8 191 96.0 27.5 76 38.2 28.8 146 73.4 30.4 50 25.1 32.5 43 21.6 5 Form IV was characterized by DSC. The DSC was obtained using similar conditions as those for Form I. The DSC thermogram is shown in Figure 27. The DSC thermogram revealed endothermic events at an onset temperature of 49.1 °C with a peak temperature of 53.6 °C and at peak temperature of 125.1. The DSC thermogram also revealed an exothermic event with an onset temperature 153.5 °C with a peak temperature of 171.1 °C. 10 Form IV was characterized by TGA. The TGA was obtained using similar conditions as Form I. The TGA thermogram is shown in Figure 28. Example 21. Preparation and Characterization of Form IVa 15 Form IVa was prepared by drying Form IV under vacuum at 45-50 °C overnight and air-dried for 28 days. Form IVa was characterized by XRPD. The XRPD was obtained using similar conditions as those for Form I. The XRPD pattern is shown in Figure 29 and the XRPD data are provided in Table 15. 89 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 Table 15 2-Theta Height H% 6.4 1419 82.2 6.9 1727 100 8.7 349 20.2 10.1 927 53.7 11.0 40 2.3 13.8 134 7.8 14.4 668 38.7 14.7 96 5.6 15.6 130 7.5 16.5 56 3.2 17.5 90 5.2 17.8 80 4.6 18.3 47 2.7 20.1 63 3.6 20.7 328 19.0 20.9 175 10.1 21.6 239 13.8 22.1 547 31.7 22.8 1373 79.5 23.3 83 4.8 23.7 68 3.9 24.4 1657 95.9 24.7 554 32.1 25.1 53 3.1 25.6 69 4.0 26.2 79 4.6 27.2 130 7.5 27.8 111 6.4 28.5 630 36.5 29.0 68 3.9 29.6 40 2.3 30.2 147 8.5 31.2 62 3.6 31.4 168 9.7 32.1 136 7.9 32.6 97 5.6 33.3 58 3.4 34.6 98 5.7 35.9 138 8.0 36.6 64 3.7 38.0 39 2.3 90 5 10 15 20 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 39.0 84 4.9 39.6 53 3.1 40.9 75 4.3 41.3 64 3.7 42.2 68 3.9 42.7 75 4.3 44.1 44 2.5 Form IVa was characterized by DSC. The DSC was obtained using similar conditions as those for Form I. The DSC thermogram is shown in Figure 30. The DSC thermogram revealed an endothermic event at an onset temperature of 50.1 °C with a peak temperature of 53.3 °C and an exothermic event with a peak temperature of 182.9 °C. Form IVa was characterized by TGA. The TGA was obtained using similar conditions as Form I. The TGA thermogram is shown in Figure 31. Example 22. Preparation and Characterization of Form V In one experiment. Form V was prepared by evaporating approximately 2 mL of saturated solution of Form I in acetonitrile under air without stirring at 25 ± 1 °C. Form V was also prepared according to the procedure set forth in Example 11 by evaporating a solution of compound I in MeCN, EtOH or 1-propanol at 50 °C. In other experiments, Form V was prepared according to the procedures set forth in Examples 13, 14 and 15 using MeCN/MTBE or MeCN/IPAc as a solvent pair in antisolvent addition; MeCN/MTBE, MeCN/IPAc as a solvent pair in reverse addition; and MeCN in quench cooling Form V was characterized by XRPD. The XRPD was obtained using similar conditions as those for Form I. The XRPD pattern is shown in Figure 32 and the XRPD data are provided in Table 16. Table 16 2-Theta 5.6 Height 772 H%43.5 7.3 1773 100 9.4 147 8.3 10.8 464 26.2 14.1 71 4.0 14.8 261 14.7 15.9 259 14.6 91 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 16.7 484 27.3 17.6 501 28.3 18.3 187 10.5 19.3 201 11.3 20.1 368 20.8 21.2 1293 72.9 21.6 696 39.3 23.3 383 21.6 24.3 870 49.1 25.4 324 18.3 25.9 69 3.9 26.9 323 18.2 27.9 190 10.7 29.8 191 10.8 30.6 105 5.9 31.3 109 6.1 31.7 97 5.5 32.5 142 8.0 33.3 78 4.4 34.0 60 3.4 37.0 89 5.0 38.2 93 5.2 39.8 167 9.4 41.9 56 3.2 42.6 83 4.7 44.0 79 4.5 Form V was characterized by DSC. The DSC was obtained using similar conditions as those for Form I. The DSC thermogram is shown in Figure 33. The DSC thermogram revealed endothermic events at an onset temperature of 47.4 °C with a peak temperature of 5 52.9 °C and an onset temperature at about 72.3 °C with a peak temperature of 82.9 °C. The DSC thermogram also revealed an exothermic event at an onset temperature of 176.7 °C with a peak temperature of 184.8 °C. Form V was characterized by TGA. The TGA was obtained using similar conditions as Form I. The TGA thermogram is shown in Figure 34. 10 Example 23. Preparation and Characterization of Form VI In one experiment. Form VI was prepared by evaporating approximately 2 mL of saturated solution of Form I in dichloromethane under air without stirring at 25 ± 1 °C. Form 92 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 VI was also prepared according to the procedure set forth in Example 11 by evaporating a solution of Compound I in 2-methoxyethanol or IPA at 50 °C. Form VI was characterized by XRPD. The XRPD was obtained using similar conditions as those for Form I. The XRPD pattern is shown in Figure 35 and the XRPD data 5 are provided in Table 17. Table 17 2-Theta 5.6 Height 63 H%3.0 7.4 308 14.5 9.4 75 3.5 9.7 84 3.9 10.9 280 13.2 14.1 310 14.6 14.6 78 3.7 16.0 268 12.6 17.1 386 18.1 17.7 262 12.3 18.3 179 8.4 19.1 222 10.4 20.4 579 27.2 21.3 1059 49.7 22.0 228 10.7 22.8 1291 60.6 23.5 542 25.5 24.5 2129 100 25.7 423 19.9 27.2 166 7.8 27.8 119 5.6 28.6 400 18.8 30.3 446 20.9 31.8 313 14.7 32.8 206 9.7 33.8 120 5.6 35.1 203 9.5 36.8 207 9.7 38.5 237 11.1 41.5 107 5.0 42.7 251 11.8 Form VI was characterized by DSC. The DSC was obtained using similar conditions as those for Form I. The DSC thermogram is shown in Figure 36. The DSC thermogram 10 revealed an endothermic event at an onset temperature of 66.5 °C with a peak temperature of 93 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 82.1 °C and an exothermic event at an onset temperature of 148.5 °C with a peak temperature of 184.9 °C. Form VI was characterized by TGA. The TGA was obtained using similar conditions as Form I. The TGA thermogram is shown in Figure 37. 5 Example 24. Preparation and Characterization of Form VII Form VII was prepared by evaporating approximately 2 mL of saturated solution of Form I in ethanol under air without stirring at 25 ± 1 °C. 10 Form VII was characterized by XRPD. The XRPD was obtained using similar conditions as those for Form I. The XRPD pattern is shown in Figure 38 and the XRPD data are provided in Table 18. Table 18 2-Theta 11.0 Height 65 H%4.1 14.4 145 9.2 16.3 71 4.5 17.2 255 16.1 18.0 78 4.9 18.5 124 7.8 19.3 102 6.4 21.6 786 49.7 23.0 802 50.7 23.8 256 16.2 24.8 1582 100 25.6 229 14.5 26.0 366 23.1 26.4 251 15.9 27.5 95 6.0 28.9 142 9.0 30.1 190 12.0 30.5 334 21.1 32.1 190 12.0 33.0 143 9.0 34.2 77 4.9 34.9 102 6.4 35.4 226 14.3 37.2 170 10.7 94 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 38.9 144 9.1 40.2 96 6.1 40.9 69 4.4 41.6 82 5.2 42.6 115 7.3 43.0 177 11.2 Form VII was characterized by DSC. The DSC was obtained using similar conditions as those for Form I. The DSC thermogram is shown in Figure 39. The DSC thermogram revealed an endothermic event at an onset temperature of 81.2 °C with a peak temperature of 5 90.3 °C and an exothermic event at an onset temperature of 148.8 °C with a peak temperature of 184.9 °C. Form VII was characterized by TGA. The TGA was obtained using similar conditions as Form I. The TGA thermogram is shown in Figure 40. 10 Example 25. Preparation and Characterization of Form VIII Form VIII was prepared by evaporating approximately 2 mL of saturated solution of Form I in w-butanol under air without stirring at 50 ± 1 °C. Form VIII was characterized by XRPD. The XRPD was obtained using similar 15 conditions as those for Form I. The XRPD pattern is shown in Figure 41 and the XRPD data are provided in Table 19. Table 19 2-Theta 7.2 Height 646 H%24.4 9.4 49 1.8 10.6 186 7.0 14.7 252 9.5 15.8 163 6.2 16.3 924 34.9 17.5 380 14.3 18.1 340 12.8 19.0 83 3.1 20.7 986 37.2 21.5 919 34.7 22.6 777 29.3 23.8 2650 100 24.8 1020 38.5 95 5 10 15 20 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 25.7 185 7.0 27.4 1366 51.5 29.4 452 17.1 30.4 487 18.4 31.2 163 6.2 32.2 279 10.5 33.1 112 4.2 33.8 321 12.1 36.1 215 8.1 37.2 143 5.4 39.4 216 8.2 40.5 143 5.4 41.9 297 11.2 43.2 159 6.0 Form VIII was characterized by DSC. The DSC was obtained using similar conditions as those for Form I. The DSC thermogram is shown in Figure 42. The DSC thermogram revealed an endothermic event at an onset temperature of 69.7 °C with a peak temperature of 74.7 °C and an exothermic event at an onset temperature of 157.0 °C with a peak temperature of 185.9 °C. Form VIII was characterized by TGA. The TGA was obtained using similar conditions as Form I. The TGA thermogram is shown in Figure 43. Example 26. Preparation and Characterization of Form IX In one experiment, Form IX was prepared by adding 0.3 mL of a solution of Form I in n-butanol (50 mg/mL) to 2.0 mL of heptane followed by stirring for about 5 min. The resulting solid was filtered. Form IX was also prepared according to the procedure set forth in Example 13 using «-BuOH/MTBE or n-BuOH/heptane as a solvent pair. Form IX was characterized by XRPD. The XRPD was obtained using similar conditions as those for Form I. The XRPD pattern is shown in Figure 44 and the XRPD data are provided in Table 20. Table 20 2-Theta Height H% 3.3 36 1.1 5.3 3233 100 96 5 10 15 20 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 6.9 73 2.3 10.5 498 15.4 15.7 252 7.8 16.3 612 18.9 21.0 309 9.6 21.4 366 11.3 22.8 118 3.6 25.0 29 0.9 26.7 454 14.0 27.8 50 1.5 32.0 156 4.8 33.0 27 0.8 37.1 25 0.8 38.3 31 1.0 Form IX was characterized by DSC. The DSC was obtained using similar conditions as those for Form I. The DSC thermogram is shown in Figure 45. The DSC thermogram revealed an endothermic event at an onset temperature of 76.6 °C with a peak temperature of 81.9 °C and an exothermic event at an onset temperature of 154.4 °C with a peak temperature of 185.9 °C. Form IX was characterized by TGA. The TGA was obtained using similar conditions as Form I. The TGA thermogram is shown in Figure 46. Example 27. Preparation and Characterization of Form X In one experiment, Form X was prepared by adding 0.3 mL of saturated solution of Form I in ethanol (60 mg/mL) to 2.5 mL of heptane. The resulting solid was filtered. Form X was also prepared according to the procedure set forth in Example 13 using EtOH/heptane as a solvent pair. Form X was characterized by XRPD. The XRPD was obtained using similar conditions as those for Form I. The XRPD pattern is shown in Figure 47 and the XRPD data are provided in Table 21. Table 21 2-Theta Height H% 5.3 2417 45.7 6.9 5290 100 97 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 9.0 289 5.5 10.4 1236 23.4 11.4 96 1.8 13.8 148 2.8 14.5 782 14.8 15.7 179 3.4 16.4 1610 30.4 18.0 677 12.8 18.8 137 2.6 20.8 3645 68.9 21.5 551 10.4 22.9 991 18.7 23.2 254 4.8 24.0 2250 42.5 25.0 978 18.5 26.7 618 11.7 27.6 291 5.5 29.7 65 1.2 31.0 176 3.3 31.5 288 5.4 32.1 471 8.9 33.0 85 1.6 34.6 80 1.5 36.7 200 3.8 38.4 55 1.0 39.7 152 2.9 41.7 125 2.4 Form X was characterized by DSC. The DSC was obtained using similar conditions as those for Form I. The DSC thermogram is shown in Figure 48. The DSC thermogram revealed an endothermic event at an onset temperature of 73.8 °C with a peak temperature of 5 79.2 °C and an exothermic event at an onset temperature of 149.7 °C with a peak temperature of 185.1 °C. Form X was characterized by TGA. The TGA was obtained using similar conditions as Form I. The TGA thermogram is shown in Figure 49. 10 Example 28.Preparation and Characterization of Form XI 98 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 Form XI was prepared as follows. About 2.0 mL of saturated solution of Form I in npropanol was cooled to -20 °C and kept at -20 °C for 1 h to give slurry. The resulting solid was filtered and air-dried for 1 h. Form XI was characterized by XRPD. The XRPD was obtained using similar 5 conditions as those for Form I. The XRPD pattern is shown in Figure 50 and the XRPD data are provided in Table 22. Table 22 2-Theta Height H% 5.1 5949 100 6.7 2049 34.4 10.1 104 1.7 11.2 49 0.8 14.1 69 1.2 15.5 466 7.8 16.1 1975 33.2 17.0 238 4.0 17.4 46 0.8 17.8 255 4.3 18.7 59 1.0 19.6 99 1.7 20.3 448 7.5 20.7 2654 44.6 21.1 1098 18.5 22.5 1000 16.8 22.8 90 1.5 23.4 892 15.0 24.6 388 6.5 24.9 95 1.6 25.9 491 8.3 26.3 226 3.8 26.8 63 1.1 27.4 631 10.6 29.2 168 2.8 30.3 152 2.6 30.7 45 0.8 31.2 91 1.5 31.6 473 8.0 32.3 90 1.5 32.6 96 1.6 34.0 172 2.9 36.0 45 0.8 99 5 10 15 20 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 36.6 416 7.0 37.7 101 1.7 39.1 71 1.2 40.9 115 1.9 43.2 62 1.0 44.3 115 1.9 Form XI was characterized by DSC. The DSC was obtained using similar conditions as those for Form I. The DSC thermogram is shown in Figure 51. The DSC thermogram revealed an endothermic event at an onset temperature of 77.3 °C with a peak temperature of 82.1 °C and an exothermic event at an onset temperature of 153.7 °C with a peak temperature of 185.7 °C. Form XI was characterized by TGA. The TGA was obtained using similar conditions as Form I. The TGA thermogram is shown in Figure 52. Example 29. Preparation and Characterization of Form XII Form XII was prepared as follows. Approximately 7 mL of saturated solution of Form I in acetone was prepared at about 30 °C and cooled to 25 °C in a bath slowly by using a programmed circulating bath. The resulting solution was heated to 50 °C over 2 hours and then cooled to 5 °C over 2 hours, and this process was repeated for 80 hrs. The resulting solid was filtered and air-dried. Form XII was characterized by XRPD. The XRPD was obtained using similar conditions as those for Form I. The XRPD pattern is shown in Figure 53 and the XRPD data are provided in Table 23. Table 23 2-Theta 5.1 Height 956 H%80.3 6.8 1190 100 8.8 120 10.1 9.2 140 11.8 10.3 345 29.0 13.5 264 22.2 14.0 74 6.2 15.4 331 27.8 16.5 262 22.0 17.2 260 21.8 100 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 17.8 115 9.7 18.6 155 13.0 19.7 267 22.4 20.1 231 19.4 20.8 633 53.2 21.3 69 5.8 21.7 192 16.1 22.2 750 63.0 23.0 243 20.4 23.9 1072 90.1 25.2 140 11.8 25.5 105 8.8 25.9 81 6.8 26.7 83 7.0 27.2 55 4.6 28.1 180 15.1 28.7 45 3.8 29.2 47 3.9 29.8 156 13.1 31.2 120 10.1 32.3 61 5.1 34.6 65 5.5 36.3 70 5.9 37.5 45 3.8 38.1 70 5.9 41.0 41 3.4 42.2 56 4.7 Form XII was characterized by DSC. The DSC was obtained using similar conditions as those for Form I. The DSC thermogram is shown in Figure 54. The DSC thermogram revealed an endothermic event at an onset temperature of 73.9 °C with a peak temperature of 5 80.5 °C and an exothermic event at an onset temperature of 153.8 °C with a peak temperature of 185.2 °C. Form XII was characterized by TGA. The TGA was obtained using similar conditions as Form I. The TGA thermogram is shown in Figure 55. 10 Example 30.Preparation and Characterization of Amorphous Solid In one experiment, the amorphous solid of Compound I di-tosylate salt was prepared as follows. To about 3 mL of saturated or cloudy solution of Form I in 1,4-dioxane was added 101 5 10 15 20 CA 02995361 2018-02-09 WO 2017/027678 PCT/US2016/046497 about 30 mg of Form I followed by stirring at 25 ± 1 °C for 2 days. The resulting solid was filtered. The amorphous form of Compound I di-tosylate salt was also prepared according to the procedure set forth in Example 13 using THF/heptane, THF/MTBE, THF/hexane, MEK/heptane or MEK/hexane as a solvent pair. The amorphous solid was characterized by XRPD. The XRPD was obtained using similar conditions as those for Form I. The XRPD pattern is shown in Figure 56. Example 31. Stability of Polymorphic Forms In order to evaluate the relative stability relationship of the various Compound I di¬ tosylate polymorph forms, a competitive slurry experiment with a mixture of Form I, II, III and Illa through Form XII was conducted in butanone-heptane at 50 °C according to Procedure 1 below and in butanone at 25 °C according to Procedure 2 below. The mixture of thirteen polymorphs was converted to Form I after stirring in butanone/heptane (1:1) at 50 °C for 6-18 hours and after stirring in butanone at 25 °C for 6-18 hours. These results indicate that the Form I is the most stable polymorphic form in butanone and butanone/heptane (1:1). Procedure 1 competitive experiment in butanone-heptane at 50 °C: No. Operation 1 heptane (1:1) to a 4 mL vial.Added 3 mg of Compound I di-tosylate Form I to the solution in the step 1, and Added 2.5 mL of saturated solution of Compound I di-tosylate in butanone 2 stirred the resulting mixture to give a cloudy solution.To the cloudy solution of step 2 was added a mixture of 3 mg each of Compound I 3 polymorphs (Form II, III, Illa, IV, V, VI, VII, VIII, IX, X, XI, and XII).Stirred the slurry of step 3 for 6 h at 50 °C: partial slurry was filtered and analyzed 4 by XRPD, which showed Form I.Stirred the slurry in the step 3 for 18 h at 50 °C: partial slurry was filtered and 5 analyzed by XRPD, which showed Form I. Procedure 2 competitive experiment in butanone at 25 °C: No. Operation 1 4 mL vial.Added 3 mg of Compound I di-tosylate Form I to the solution in the step 1, and Added 2.5 mL of saturated solution of Compound I di-tosylate in butanone to a 2 stirred the resulting mixture to give a cloudy solution. 102 84193183 3 To the cloudy solution of step 2 was added a mixture of 3 mg each of Compound I polymorphs (Form II, III, Illa, IV, V, VI, VII, VIII, IX, X, XI, and XII). 4 Stirred the slurry in the step 3 for 6 h at 25 °C: partial slurry was filtered and analyzed by XRPD, which showed Form I. 5 Stirred the slurry in the step 3 for 18 h at 25 °C: partial slurry was filtered and analyzed by XRPD, which showed Form I. Example A: LSD1 histone demethylase biochemical assay LANCE™ LSDI/KDMIA demethylase assay- 10 uL of 1 nM LSD-1 enzyme (ENZO BML-SE544-0050) in the assay buffer (50 mM Tris, pH 7.5, 0.01% Tween™-20, 25 mM NaCL 5 5 mM DTT) were pre-incubated for 1 hour at 25 °C with 0.8 pL compound/DMSO dotted in black 384 well polystyrene plates. Reactions were started by addition of 10 pL of assay buffer containing 0.4 pM Biotin-labeled Histone H3 peptide substrate: ART-K(Mel)- QTARKSTGGKAPRKQLA-GGK(Biotin) SEQ ID NO:1 (AnaSpec 64355) and incubated for 1 hour at 25°C. Reactions were stopped by addition of 10 pL IX LANCE Detection 10 Buffer (PerkinElmer CR97-100) supplemented with 1.5 nM Eu-anti-unmodified H3K4 Antibody (PerkinElmer TRF0404), and 225 nM LANCE Ultra Streptavidin (PerkinElmer TRF102) along with 0.9 mM Tranylcypromine-HCl (Millipore™ 616431). After stopping the reactions plates were incubated for 30 minutes and read on a PHERAstar FS plate reader (BMG Labtech). The salts of the present disclosure have been tested and found to be active 15 against LSD1 with an ICso less than 100 nM. Various modifications of the invention, in addition to those described herein, will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the invention. 103 Date Reçue/Date Received 2023-01-27